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Chapter 1 II 
Introduction 
H eart failure is a clinical syndrome with various causes for which no universally accepted definition exists.' Packer's definition of heart failure "representing a 
complex clinical syndrome characterised by abnonnalities of left ventricular function 
and neurohumoral regulation. which are accompanied by effort intolerance, fluid 
retention and reduced longevity" reveals the complexity of the syndrome.2 
Heart failure is one of the commonest cardiovascular disorders in Western Society and a 
growing major public health problem. It has been estimated that in the Netherlands the 
number of hospital discharges for heart failure rose from 14441 in 1980 to 25966 in 
1993.3 The prevalence of heart failure rises rapidly with age from 0.7% in those aged 
55-64 to 13.0% in those aged 74-84.4 This indicates a rapidly expanding problem 
mainly due to an increase in the number of elderly. 
Despite the facl that heart failure and its precursor left ventricular systolic dysfunction 
are increasingly being recognised as important causes for morbidity and mortality, 
epidemiologic data are scarce. l For example, reliable information on the incidence of 
the syndrome is very limited. One of the reasons of the lack of epidemiologic data on 
heart failure is the difficulty of diagnosing early slages of heart failure and the virtual 
absence of target cohort studies. In the Netherlands and in the UK most heart failure 
patients are detected and treated in general practice. Heart failure is difficult to diagnose 
by the general practitioner due to the unavailability of morc sophisticated or invasive 
diagnostic tools and is primarily based on clinical judgement. In recent years 
neurohumoral and Doppler echocardiographic measurements have emerged as non-
invasive tools that could aid in the diagnosis of heart failure, also in a non-hospital 
setting.5-8 
Heart fallure carries a poor prognosis, but, again, data from population-based studies, 
notably those addressing the prognostic implications of asymptomatic ventricular 
dysfullction, is limited. 
In recent decades the therapeutic management of heart failure has changed dramatically. 
Currently available treatment options (e.g. ACE-inhibitors, ll-blockers, diuretics and 
spironolactone) can reduce morbidity and mortality.9-13 Moreover, it is suggested that in 
asymptomatic patients with left ventricular dysfunction prognosis can be improved by 
means of ACE-inhibition.9•14 It is therefore important to identify determinants of the 
presence or development of heart failure and left ventricular dysfunction, to enable 
targeting of effective preventive or therapeutic strategies. The Rotterdam Study 
provided an excellent opportunity to study some ofthe issues mentioned above. 
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In the following chapters of this thesis, various epidemiologic aspects of heart failure 
and its precursor left ventricular systolic function will be addressed. In chapter 2 of this 
thesis, an overview of the epidemiology of asymptomatic left ventricular systolic 
function in the general population is presented. Reproducibility of the use of a heart 
failure score by general practitioners is described in chapter 3. Chapter 4 reports on the 
incidence and management of heart failure in general practice using data from the Dutch 
National Survey of Morbidity and Interventions in General Practice (NIVEL). hl 
chapter 5 a study on the incidence and risk factors of heart failure is presented. The 
diagnostic value of the measurement of neurohormones to assess the presence of heart 
failure in patients suspected of heart failure is presented in chapter 6. Prognostic 
implications of left ventricular dysfunction and heart failure in the population at large 
are provided in chapter 7 and 8. Finally, in chapter 9 the results presented in the 
foregoing chapters are discussed and suggestions for further research are given. 
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Introduction 
H eart failure is very common, especially in the elderly, and has become one of the most important health care problems in cardiovascular medicine. The public 
health and economic burden of heart failure is expected to increase further due to ageing 
of the population and the success in treatment of cardiac diseases, notably ischaemic 
heart disease. 1,2 The prognosis of patients with heart failure is poor; within 5 years of a 
diagnosis of heart failure in the Framingham Heart Study, 75% of the men and 62% of 
the women had died.3 Heart failure is a clinical syndrome that largely defies definition. 
The working group on heart failure of the European Society of Cardiology emphasized 
that the definition of heart failure encompasses objective evidence of cardiac 
dysfunction and clinical symptoms.4 Thus, heart failure could be defined as 
symptomatic left ventricular dysfunction. \Vhen no symptoms are present, the term 
asymptomatic left ventricular dysfunction should be used. Left ventricular dysftmction 
can be attributable to systolic dysfunction, diastolic dysfunction or both. Hospital-based 
studies have shown that impaired systolic function is associated with a poorer prognosis 
in patients with myocardial infarction or congestive heart failure. Several studies have 
demonstrated the prognostic benefits of treatment of symptomatic left ventricular 
dysfunction (i.e. heart failure).5-lo Asymptomatic systolic left ventricular dysfunction is 
increasingly being recognized as an important precursor of heart failure; 30% of the 
participants in the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial 
with asymptomatic impaired systotic function developed symptoms within three years,? 
Theoretically, prevention and early detection and treatment of asymptomatic systolic 
dysftmction might lead to a significant reduction of morbidity and mortality in the 
elderly. Epidemiologic data on left ventricular systolic dysnmction (LVSD) in the 
population at large are, however, scarce, I I Even less is known about left ventricular 
diastolic dysnmction. 12,13 Most patients with heart failure and left ventricular diastolic 
dysfunction also have LVSD. In the study reported by Cowie et al. less than 15% of the 
incident cases of hearl failure predominantly had left ventricular diastolic dysfunclion. 14 
Currently, no standardized method exists to establish diastolic dysnmction and specific 
treatment options for left ventricular diastolic dysfunction are lacking. For those 
reasons, left ventricular diastolic dysfunction will not be addressed in the following. 
Echocardiography is recommended as the most appropriate diagnostic tool to assess the 
presence of cardiac dysnmction. Echocardiography has only recently been used in 
population-based studies and in studies in general practice to determine the occurrence 
ofleft ventricular dysfunction. 
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In tlus article, we will give an overview of recent data on the epidemiology of left 
ventricular systolic (dys)function in the general population, with emphasis on 
asymptomatic left ventricular systolic dysfunction. 
Methods 
The Medline Literature Database from January 1966 till April 1999 was searched using 
the medical subject headings "heart failure (congestive)", "cardiomyopathy 
(congestiveY', "left ventricular function" and "epidemiology". In addition, we searched 
for the text words "symptomless l " "asymptomatic", "symptomatic", "systolic function", 
"general practice", "primary care" and "general population", The search was extended 
using lateral references and personal communications with investigators. 
Diagnosis 
Left ventricular systolic dysfunction is a diminished ability of the heart to contract 
against a load; the ventricle has a reduced capacity to eject blood into a high-pressure 
aorta and the ejection fraction is reduced. IS There are several methods by which left 
ventricular systolic function can be measured. Clinical findings, for example previous 
myocardial infarction, dyspnoe, oedema, rales and electrocardiographic abnormalities 
such as atrial fibrillation are not useful in detecting left ventricular dysfunction. 16 
Traditionally, left ventricular function (pump performance) is measured during cardiac 
catheterization and contrast left ventricular angiography. The invasive nature of this 
procedure largely precludes its use in population-based studies. There are four non-
invasive methods to assess left ventricular function: radionuclide angiography, electron-
beam computed tomography (EBCT) scanning, ultrafast magnetic resonance imaging 
(MRl) and echocardiography. Nuclear angiography exposes patients to radiation and is 
relatively expensive. Although EBCT and MRl are highly reproducible and accurate in 
determining left ventricular function, they are not widely available, expensive and the 
cost-effectiveness of EBCT and MRl scans compared to echocardiography has not been 
adequately evaluated. 17-20 Up till now, MRI has only been used in highly selected 
patient groups. Furthermore, an MRl scan is judged to be unpleasant by many patients 
because they have to lie still for quite some time in a very noisy surrounding. 
Furthermore, MRl assessment of left ventricular function is time-consuming, both on-
and off-line, making it unsuitable for rapid assessment. For the assessment of 
Asymptomatic LVSD in the general population 
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ventricular function with EBer, contrast has to be administrated intravenously and the 
patient is exposed to high radiation. Therefore, echocardiography is most widely used in 
clinical practice and seems a suitable tool for assessment of left ventricular systolic 
function in the population at large. From 2D echocardiographic images, left ventricular 
end-diastolic volume (EDV) and end-systolic volume (ESV) can be determined and the 
ejection fraction (EF), an index of left ventricular function can be calculated. Ejection 
fraction is the ratio of the difference between EDV and ESV to EDV and is expressed as 
a percenlage (EF(%)~(EDV-ESV)IEDVxIOO). There are different methods (e.g. 
Simpson's rule, single and biplane ellipse methods) to determine left ventricular 
volumes, which are all tedious and timcMconsuming measurements. Left ventricular 
syslolic function can also be estimated more simply by calculating the fractional 
shortening (FS) as the difference between left ventricular internal dimension at end 
diastole (LVIDed) and left ventricular internal dimension at end systole (LVIDes) 
divided by LVIDed (FS(%)~(LVIDed-LVIDes)ILVIDedxlOO). In the absence of major 
wall motion abnormalities fractional shortening can be assumed to reliably reflect left 
ventricular systolic function,21 Furthermore, a semi-quantitative visual assessment of 
left ventricular function is sometimes used, since calculation of the ejection fraction is 
not always possible in routine medical practice. These visual estimates by experienced 
observers correlate reasonably well with the ejection fraclion measured by radionuclide 
scan,16,22 
Usually, the ventricle ejects more than 50% of its end-diastolic volume, but it is 
generally accepted that a ejection fraction of less than 40% can be considered abnormal. 
However, different cut-off values are used. Precise measurements of left ventricular 
function with echocardiography are not always possible, because a suitable 
echocardiographic window can not always be obtained. This is particularly prevalent in 
subjecls with obesity and/or pUlmonary disease and in the very old. Furthennore, atrial 
fibrillation reduces the reliability of the left ventricular systolic function measurements. 
Routine application of echocardiography requires considerable expertise, is 
time-consuming and resource availability is limited.23 Prescreening using prediction 
rules based, on signs and symptoms or on electrocardiography and neurohormone 
assessment may help to target echocardiography at those subjects most likely to have 
left ventricular dysfunction, but up to the present, the effectiveness of such prescreening 
strategies has not been addressed. 
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Prevalence 
Estimates of the prevalence of left ventricular systolic dysfunction in the general 
population are available from five recent studies. I 1,24-27 The estimates vary 
considerably. This is mainly attributable to differences in methodology (table I). 
Estimates of asymptomatic LVSD are given in three studies only. 
In the Rotterdam Study, a community-based prospective cohort study in 
Rotterdam, The Netherlands, the presence of heart failure was determined in 5540 
participants aged 55 years or over (mean age 69 years, 41% male). I I In 2267 subjects 
M-mode echocardiography was performed. Left ventricular dysnmction was defined as 
a fractional shortening of25% or lower (comparable to an ejection fraction of <; 42.5%). 
In about 20%, M-mode registrations were deemed inadequate to measure fractional 
shortening. The overall prevalence of impaired systolic nmction was 5.5% (95% CI 4.1-
7.0) in men and 2.2% (95% CI 1.4-3.2) in women. Sixty percent of persons with left 
ventricular systolic dysfunction was asymptomatic, i.e. did not report symptoms or had 
signs of heart failure, such as shortness of breath, ankle edema or pulmonary 
crepitations. 
In the Glasgow MONICA risk factor survey among 2000 participants, the 
prevalence of left ventricular dysfunction was detenuined in 1640 participants aged 25-
74 years (mean age 50 years; 48% male).'5 All participants underwent 
echocardiography and ejection fraction was assessed by the biplane Simpson's rate 
method. Left ventricular systolic dysfunction was defined as an ejection fraction of 30% 
or lower. Ejection fraction was measurable in approximately 90% of the participants. 
The prevalence of impaired systolic nmction was 2.9% (95% CI not given), was higher 
in men than in women (respectively 4.0% and 2.0%) and clearly increased with age. 
Impaired systolic nmction was asymptomatic in about half of the cases. With systolic 
dysfunction defined as an ejection fraction of less than 35% the overall prevalence was 
7.7%, with 77% being asymptomatic. 
In the study by Morgan et aI, the prevalence of impaired ventricular function 
was assessed in a random sample of 1200 subjects aged 70-84 years (mean age 76 
years; 46% male) enlisted with a four centre group general practice in Poole, Dorset.24 
Impaired systolic function was determined qualitatively in 1056 subjects eligible for 
echocardiography and quantitatively by measuring the biplane Simpson's rate method 
in 817 patients (77.4%). This yielded overall prevalence estimates of impaired systolic 
nmction of 7.5% (95% CI 5.8-9.5); 12.8% in men and 2.9% in women. Approximately 
50% of those with systolic dysfunction had been diagnosed with heart failure before. 
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Table 1: Prevalence ofleft ventricular systolic dysfunction in the general population 
Age Rotterdam Studyll MONlCA" Morgan24 
(years) (FS $15%; mean age 69) (EF :$;30%; mean age 50) (EF qual; mean age 76) 
(n=2267) (n=1467) (n=817) 
Men Women All Men Women All Men Women All 
25-34 0 0 
35-44 0.7 0 
45-54 5.8 2.4 
55-64 3.7 1.2 2.3 5.7 2 
65-69 7.6 3.1 5.3 6.4 4.9 
70-74 6.9 3.3 4.8 9.4 2.2 5.8 75-79 13.1 2.4 6.9 
80-84 
85-94 10.0 10.5 10.3 
20.5 5.4 12.1 
Total 5.5 2.2 3.7 4.0 2.0 2.9 12.8 2.9 7.5 
FS "'" fractional shortening, EF = ejection fraction, qual = assessed qualitatively, - = not reported 
CHS26 
(EF qual; roean age 73) 
(n=5069) 
Men women All 
2.3 
3.6 
5.2 
5.5 
6.3 1.8 
Framingham27 
(FS ::s; 30%; mean age 46) 
(n=1493) 
Men Women All 
5.1 
() 
=-
" 
'" 
-
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The Cardiovascular Health Study from the USA estimated the prevalence ofleft 
ventricular dysfunction in 5069 participants aged 65 years and older (mean age 73 
years; 43% male).26 Left ventricular function was assessed qualitatively in 99% of the 
participants. Again, the prevalence of impaired systolic function was higher in men 
(6.3%) than in women (1.8%). No estimates of the prevalence of asymptomatic LVSD 
were given. 
In a subgroup of 1493 men (mean age 46 years; 100% male) free from overt 
cardiovascular disease of the Framingham Heart Study the overall prevalence of 
asymptomatic left ventricular dysfunction was 5.1% (95%CI not given).27 Impaired 
systolic fimction was defined as a fractional shortening,; 30%. 
Despite large differences in the applied definitions of left ventricular 
dysfunction, geographic regions and populations, resulting in different prevalence 
estimates, these studies clearly indicate that left ventricular systolic dysfunction is 
conmlon, and that its prevalence strongly increases with age and is considerably higher 
in men than in women. In addition, LVSD is not accompanied by symptoms of heart 
failure in about 50% of the cases. 
Incidence 
As far as we know no data on the incidence of asymptomatic left ventricular systolic 
dysfimction are available. For symptomatic LVSD (i.e. heart failure) the only available 
population based data come from a study by Cowie et al. 14 In tills study incident cases 
of heart failure were identified through a rapid access outpatient heart failure clinic to 
which GPs referred all cases of suspected heart failure and through examining all 
hospital admissions for heart failure. A panel of three cardiologists decided on the 
presence of heart failure using the guidelines of the Task Force on Heart Failure of the 
European Society of Cardiology.4 The overall incidence was 1.3 per 1000 person-years; 
1.4 in men and 1.2 in women. LVSD was found to be present in more than 85% of the 
incident cases of heart failure. Ideally, the incidence of asymptomatic LVSD should be 
studied in a population-based prospective cohort study using echocardiography to assess 
ventricular filllction. The baseline prevalent cases with LVSD should be excluded and 
during regular repeated echocardiographic assessments the presence of L VSD should be 
studied in all other subjects. Such a study, however, is logistically difficult, time 
consuming and expensive. 
Asymptomatic LVSD in the general population 
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Etiology 
Although much remains to be learned about the etiology of heart railure, coronary artery 
disease, diabetes and hypertension have been identified as the main risk factors in 
Western societies. As rar as we know only McDonagh and Morgan et al. reported risk 
factors for left ventricular systolic dysnlllction in the general population.24,25 In the 
Glasgow Monica risk factor survey, ischaemic heart disease (i.e. history of angina, 
history of myocardial infarction and ischaemia or infarction on ECG) was found to be 
the main risk factor for LVSD. Furthermore, hypertension was an important risk factor, 
but only in the presence of ischaemic heart disease. Morgan et al. reported that self 
reported history of angina, myocardial infarction, heart failure and stroke were related to 
the presence of LVSD. However, the studies of Morgan et al and McDonagh et al were 
cross-sectional surveys. Although, cross-sectional surveys can be used in etiologic 
studies, one should keep in mind that in cross-sectional studies the determinants and 
outcome are measured at a single point in time. Cross-sectional studies designs are 
susceptible to bias (e.g. selection bias and cause-effect bias) and therefore may pose 
problems in the interpretation regarding causality. Additional prospective studies may 
provide nlrther knowledge on the etiology ofLVSD. 
Prognosis 
Little is known about the prognostic implications in terms of fuhlre cardiovasculair 
events and mortality of symptomatic and asymptomatic LVSD in the population at 
large. Currently available data originates from trials (e.g. SAVE and SOLVD) including 
selected placebo treated patients with LVSD. Population based prognostic studies in 
subjects with (asymptomatic) LVSD are urgently needed. 
Management 
Interventions could be aimed at reducing the risk of developing LVSD, decreasing the 
progression of asymptomatic L VSD to heart failure and reducing signs and symptoms 
accompanying symptomatic LVSD. 
Prevention of LVSD, the first step in the management ofLVSD, should focus on 
the modification of risk factors for LVSD, and in particular those related to the 
progression of coronary artery disease. Therefore, interventions should be directed at 
Asymptomatic LVSD iu the general populaiiol1 
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preventing, detecting and treating hypertension, diabetes, hypercholesterolemia and 
smoking. 
In subjects with asymptomatic LVSD, screening for LVSD might be useful and 
interventions should aim at postponing or preventing the development of symptomatic 
LVSD (i.e. heart failure). There are only two studies suggesting that in selected patients 
with ischaemic heart disease and asymptomatic LVSD (mean age of sixty years), 
morbidity and mortality can be reduced by treatment with ACE-inhibitors.7,10 This 
benefit needs to be confirmed in a trial with larger groups of asymptomatic LVSD 
patients, demonstrating the added value of treating those with asymptomatic LVSD 
compared to those treated when symptoms developed. Only then screening for and 
treatment of asymptomatic LVSD could be considered in a larger population. 
The treatment of heart failure has been discussed extensively in several 
guidelines.28,29In short, ACE inhibitors form the cornerstone of heart failure treatment. 
Additionally, diuretics, digoxin, spironolactone and A-blockers may be prescribed 
depending on signs and symptoms. Studies addressing the efficacy of some of these 
drugs in asymptomatic LVSD are underway. 
Summary and conclusion 
Left ventricular systolic dysfunction is common, its prevalence and incidence increases 
sharply with age, LVSD is more common in men and LVSD very often is 
asymptomatic. Left ventricular systolic dysfunction and its subsequent progression to 
heart failure places a major public health and economic burden on society. Prevention 
and early interventions may be the key to reduce this burden. Before early detection of 
or screening for and subsequent treatment of patients with asymptomatic left ventricular 
systolic dysfunction can be recommended with confidence more infonnation on its 
incidence, etiology, prognosis and therapeutic possibilities is required. 
Asymptomatic LVSD in the general population 
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Introduction 
The diagnosis of (early stages ot) heart failure is a difficult and chalienging task. This particularly applies to primary care, where the diagnosis of heart failure is 
mainly based on clinical judgement of the general practitioner (GP). Prior studies 
showed that the validity of the clinical diagnosis of heart failure is limited, particularly 
in women, the obese and the elderly.I~3 Incorrect diagnosis has major consequences for 
both patients and health services. Therefore, methods to improve the early recognition 
of heart failure are required. The presence of heart failure can be assessed with the use 
of scoring systems4 All scores have a high sensitivity for diagnosing definite heart 
failure and a much lower sensitivity for the detection of possible heart failure. The 
presentation of early stages of heart failure is atypical and the applicability of heart 
failure scores as a screening test to detect heart failure requires fiuther study. In our 
study on the incidence and risk factors of heart failure we trained general practitioners 
in the use of a score in order to refer ali possible cases of heart failure. The purpose of 
this study was to assess the interobserver variation among participating GPs in the use 
of a scoring system to detect possible heart failure. 
Methods 
TIlls study forms part of a 2.5 year follow-up study on the incidence and risk factors of 
heart failure among participants of the Rotterdam Study. The Rotterdam Study is a 
population-based study among 7983 inhabitants of 55 years and older of a suburb of 
Rotterdam. Rationale and design of the Rotterdam Study were described in detail 
elsewhere.5 For logistic reasons, we included only participants who were enlisted with 
18 general practitioners working in the Ommoord area in the incidence study. As part of 
this study, the 18 participating general practitioners were trained in the application of a 
heart failure score to standardize referral for diagnostic work-up at the research centre. 
The Rotterdam Heart Failure Score (table I) included signs, symptoms and history of a 
patient, based on the "Boston criteria for heart failure" scoring system.6 Furthermore, 
we added several criteria, based on a review of the literature, to increase sensitivity for 
case finding of heart failure patients as much as possible. During the study period, the 
GPs were asked to deternline the Heart Failure Score in all Rotterdam Study 
participants presenting with dyspnoea, progressive fatigue/anorexia of possible cardiac 
origin, paroxysmal nocturnal cough, leg oedema and nocturia and in any other 
Rotterdam Study participant suspected by the GP of having heart failure. Participants 
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who scored three or more points had to be referred for a diagnostic work-up. For the 
present study we added two questions on estimated diagnostic presence of heart failure 
to the score to assess the agreement on the presence of heart failure by the GPs. Out of 
the 18 participating GPs, five were selected randomly to take part in the present study. 
The selected GPs were asked to examine 15 patients and fill in the heart failure score. 
Table 1: Rotterdam Study heart failure score 
History 
• Rest dyspnoea 
• Orthopnoea 
• Paroxysmal noctumal dyspnoea 
• Dyspnoea on walking on level 
• Dyspnoea on climbing 
• Parox.1'smal noctumal cough 
Past histm"y 
• Myocardial infarction 
• Hypertension 
• Angina pectoris 
• CABG or PTCA 
• Atrial fibrillation 
• Heart valve disease 
• Peripheral arterial disease 
Points 
4 
4 
3 
2 
I 
2 
Physical examination 
• Heart rate 90-110 be.1lsimin 
> 110 beats/min 
• Raised jugular venous pressure 
• Raised jugular venous pressure & 
hepatomegaly or edema 
Points 
I 
2 
2 
3 
• Third heart sound I gallop rhythm 3 
• Crepitations basilar 
> basilar 
• Rhonchi 
Diagnosis 
• Heart failure present 
• Estimated as percentage 
I 
2 
3 
no/probably! yes 
..... % 
The same patients were also examined by one cardiologist (AHMMB). The patients 
were selected from participants in the Rotterdam Study registered at the practice of one 
GP (JSV). We chose to select 5 heart failure patients, I patients with chronic obstructive 
pulmonary disease (COPD) and a myocardial infarction, I patient with COPD and 
hypertension, I patient with diabetes mellitus and myocardial infarction, I obese patient 
and 6 'healthi controls. All 15 patients were invited to visit the research centre on the 
same evening. In three rounds, the five GPs and the cardiologist examined all patients. 
During each round 6 rooms were used, in five of these a participant of the Rotterdam 
Study was placed. The five GPs and the cardiologist were randomly assigned to one of 
the rooms. Within 10 minutes, the doctors had to go to the assigned room, examine the 
patient if present (one room was empty) and fill in the form. Every 10 minutes 
thereafter, the doctors rotated in a clockwise direction to the next room until each doctor 
had seen all 5 patients of the first round. The same procedure was used during rounds 
two and three. The physicians were not permitted to discuss their findings during the 
study session. 
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Table 2: Interobserver agreement. 
Intraclass correlations (95% el) 
5GPs 6 physicians* 
History 
Rest dyspnoea 0.16 (-0.04,0.42) 0.24 (0.04,0.49) 
Orthopnoea 0.44 (0.18,0.68) 0.50 (0.25,0.72) 
Paroxysmal nocturnal dyspnoea 0.00" 0.00" 
Dyspnoea on walking up-hill 0.28 (0.05,0.55) 0.30 (0.08,0.55) 
Dyspnoea on climbing 0.24 (0.02,0.50) 0.22 (0.03,0.47) 
Paroxysmal nocturnal cough 0.00'" 0.00" 
Myocardial infarction 0.82 (0.64,0.92) 0.78 (0.59,0.89) 
Hypertension 0.60 (0.34,0.79) 0.63 (0.39,0.81) 
Angina pectoris 0.46 (0.20,0.70) 0.48 (0.23,0.70) 
PTCAor CABG 0.78 (0.58,0.90) 0.82 (0.65,0.92) 
Atrial fibrillation 0.89 (0.77,0.95) 0.91 (0.81,0.96) 
Heart valve disease 0.76 (0.55,0.89) 0.80 (0.62,0.91) 
Peripheral arterial disease 0.47 (0.20,0.70) 0.53 (0.28,0.74) 
Physical examination 
Heart rate 0.43 (0.17,0.67) 0.42 (0.18,0.65) 
Raised jugular venous pressure 0.32 (0.08,0.58) 0.32 (0.10,0.57) 
Third heart sound / gallop 0.02 (-0.12,0.25) 0.05 (-0.08,0.25) 
Crepitations 0.30 (0.06,0.56) 0.21 (0.02,0.45) 
Rhonchi 0.14 (-0.05,0.39) 0.18 (0.00,0.42) 
Diagnosis 
Presence of heart failure OIl 0.40 (0.14,0.65) 0.44 (0.20,0.67) 
Presence of heart failure (estimated as %) 0.51 (0.25,0.73) 0.52 (0.27,0.73) 
Total score 
Score:?: 3 0.67 (0.43,0.84) 0.63 (0.39,0.81) 
Score in total 0.83 (0.61,0.91) 0.81 (0.64,0.91) 
.. 5 GPs and onc cardiologist. *. Could not be determined, since there was no variation behveen patients. 
Intraclass correlation coefficients were calculated along with 95% confidence intervals 
(CI) to detemline reproducibility of the heart failure score by the physicians according 
to Fisher. 7 The interobserver variability is defined as the variation in the heart failure 
score among the GPs. Intraclass correlation is the proportion of the total variability 
accounted for by the variability among subjects. If it is high not much of the variability 
is due to variability in measurements of different observers. The values of the intraclass 
correlation range from 0 to I and the strength of agreement can be interpreted as: poor 
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«0.20), fair (0.21-0.40), moderate (0.41-0.60), good (0.61-0.80) and very good (0.81-
1.00)8 
In case an item had more than two categories (e.g. heart rate, crepitations), the 
item was dichotomized (i.e. presence or absence) in the analyses. 
To determine how interobserver variability may influence the possibility of 
referral of patients for diagnostic work~up at the research centre we calculated the total 
score to determine if a patient would have been referred and we calculated the intraclass 
correlation coefficients for referral. For calculation of the total score, only the highest 
score of the dyspnoe questions was used. The same was done for heart rate, raised 
jugular venous pressure and crepitations. As mentioned above, our criterion for referral 
was a heart failure score of three or more points. All data analyses were performed 
using the SPSS statistical package 7.5.2. 
Table 3: Mean values (95% el) and ranges of tile total score or the different selected cascs. 
Total score 
Case Mean (95% el) Range 
'Healthy subjects' 
#1 1.4 (0,4.0) 0 - 5 
#2 0.2 (0,0.8) 0 - I 
#3 0.2 (0,0.8) 0 - I 
#4 1.2 (0,3.9) 0 - 5 
#5 0.4 (O,U) 0 - I 
#6 0.2 (0,0.8) 0 - I 
Heart failure patients 
#7 11.6 (9.3,13.9) 9 - 14 
#8 8.4 (5.3,11.5) 6 - 12 
#9 12.0 (6.4,17.6) 7 - 18 
#10 10.8 (7.4,14.2) 8 - 15 
#ll 7.0 (3.8,10.2) 3 - 9 
Other patients 
#12 (Obese) 4,9 (3.8,6.0) 2 - 8 
# 13 (COPD & MI) 9.4 (6.8,12.0) 8 - 13 
#14 (COPD & lIT) 3.6 (0.7,6.5) I - 6 
#15 (OM & MI) 2.8 (1.8,3.8) 2 - 4 
COPD = chronic obstructive pulmonary disease, Ml = myocardial infarction, HT = hypertension, 
DM = diabetes mellitus 
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Results 
Table 2 shows the intraclass correlations on each of the items of the heart failure score. 
Except for the variables included in the medical history as well as orthopnoea and heart 
rate, interohserver agreement was poor to fair. The agreement on the presence of heart 
failure was moderate. The agreement on referral (Le. score ;, 3) was good and 
agreement on the total score was very good. All pre-selected heart failure patients had a 
mean total score of more than three points aod were referred. All 'healthy' subjects had 
a mean total score lower than 3 points. The vast majority (94%) of these subjects would 
not be referred (table 3). 
Discussion 
Our study shows that the interobserver agreement on the presence of heart failure and 
on the signs and symptoms suggestive of heart failure "as estimated to be equal or less 
than moderate. The agreement on referral by the use of the score, however, was good. 
Furthermore, all preselected heart failure cases were referred by the GPs using the 
score. 
A limitation of our study is the number of participating subjects aod 
participating GPs, resulting in large confidence intervals. Although inclusion of the 
cardiologist enhanced the interobserver variation we do not think that the correlation 
would be higher when more GPs would have been included. Only the confidence 
intervals would have been smaller. 
The rather low intraclass correlations on the presence of heart failure may be 
partly attributable to the fact that we selected patients with disorders (such as COPD 
and obesity) known to pose difficulties in diagnosing heart failure, based on clinical 
findings only. This is illustrated in figure 1. When heart failure is evident all observers 
rate the probability of heart failure as high. When heart failure is absent all observers 
give a low rating. However, in one patient with COPD and MI the estimated probability 
on the presence of heart failure ranged from IOta 90%, thereby reducing interobserver 
agreement. 
Although the interobserver agreement on most items of the score aod on the 
presence of heart failure was low, the agreement on referral was good and referral was 
correct in all patients with documented heart failure patients. 
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We conclude that for assessment of signs, symptoms and history of heart failure 
the interobserver agreement among GPs is low. When the aim is referral of those with 
possible heart failure a heart failure score appears to be a useful tool. 
A B C D 
Observer 
E F 
• 'healthy' 
aCOPD 
EJ heart failure 
Figure 1: Example of estimated percentages of presence of heart failure by all the observers for 3 
different patients (1 healthy, I with documented COPD and myocardial infarction and J with documented 
heart failure). 
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Introduction 
H eart failure is a growing health problem in western societies. The increase in the occurrence of heart failure is mainly attributable to the ageing of the population 
and improvement in therapy of cardiovascular disorders, including ischemic heart 
disease and hypertension.! The prognosis of a patient with heart failure is poor; within 5 
years of the diagnosis heart failure in the Framingham Study, 75% of the men and 62% 
of the women died.2 Early recognition and treatment of a patient with heart failure can 
reduce the number of hospital admissions for heart failure and increase life 
expectancy.3,4 In the Netherlands and in the UK most heart failure patients are detected 
and treated in general practice. Data 011 the incidence of heart failure in primary care 
are, however, relatively scarce.5,6 Studies from the UK indicate that heart failure 
patients treated in general practice in the UK do not receive optimal treatment. 7-9 There 
is little information on the management of heart failure in the Netherlands. Such 
information is, however, crucial to facilitate the development of strategies to improve 
the care for heart failure patients. We studied the incidence of heart failure as presented 
to primary care in the Netherlands and the subsequent management of heart failure 
patients by their general practitioner. In addition, the availability of more recent data 
enabled us to study the time trends in the GP's patient management of this condition. 
Methods 
We used data from the Dutch National Survey of Morbidity and Interventions in 
General Practice, carried out in 1987 and 1988 by the Netherlands Institute of Primary 
Health Care (NIVEL), in which 161 general practitioners (GPs), with in total 74,153 
patients aged 55 years or over, participated.!O The GPs were divided in four groups. The 
four groups registered every contact between patients and the practice during 
consecutive periods of three months. The total registration period lasted from April 1st 
1987 to April 1st 1988. A special form was designed to register all contacts including 
diagnosis, referrals and prescriptions. The OPs recorded the reason for encounter in 
diagnostic temlS on the registration form. Diagnosis were coded according to the 
International Classification of Primary Care (JCPC) by specially trained coders. 
Medication was coded using the Anatomical-Therapeutical-Chemical (ATC)·code. The 
registration of morbidity in the National Survey is episode-oriented. To study the 
incidence of heart failure all new episodes registered with the ICPC-code K77 (heart 
failure) were studied. Age- and sex-specific incidence of heart failure per 1000 person 
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years with 95% confidence intervals were calculated. In addition, infonnation on 
subsequent management of these patients was studied. 
In addition, we used data of the Rotterdam General Practitioners Project 
(ROHAPRO), a computerized network of general practices in Rotterdam. Methods of 
the ROHAPRO-database are described in detail elsewhere." Briefly, the ROHAPRO-
database is a database containing demographic and medical data of in total 44,340 
patients enlisted in seven computerized general practices. Data was available from 1991 
till 1997. Information was entered in the computer by the GPs during consultation or 
afterwards in case of home-visits, and included symptoms, ICPC classified diagnoses, 
referrals, and medication. Medication is coded using the ATC-code. In addition the 
indication for medication prescription is coded routinely in ICPC-codes. Heart failure 
patients were defined as patients with the ICPC-code K77 in their patient record. 
Information on prescribed medications and referral ofthese patients were studied. 
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Figure 1: The incidence rate of heart failure in primary care in the Netherlands (per 1000 
person years) 
Results 
During the 1987-1988 (NIVEL) study period, comprising 18,538 person years, 210 
incident cases of heali failure were diagnosed by the general practitioners; 81 men and 
129 women. The overall incidence rate of heart failure was 11.3 per 1000 person years 
(95% CI 9.8-12.9); 10.0 (95 % CI 7.8-12.2) in men and 12.3 (95 % CI 10.2-14.5) in 
women. The incidence rate of heart failure increased sharply with age. In men, the 
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incidence rate increased from 2.7/1000 person years (95% CI 1.4-5.0) in those aged 55-
64 years, to 27.8/1000 person years (95% CI 19.9-35.6) in those aged >75 years, and in 
women in the same age categories from 1.7/1000 person years (95% CI 0.8-3.6) to 
33.3/1000 person years (95% CI 26.7-39.9) (Figure I). 
The GPs prescribed medication in the vast majority (77%) of the 210 cases. 
Most patients (90) received a loop diuretic, 48 another diuretic (predominantly 
thiazides), wltile only seven patients received an ACE-inhibitor (Table I). Of the 210 
incident cases of heart failure diagnosed in 1987-1988,45 (21%) were referred to a 
specialist, notably to an intentist (n~2I) or cardiologist (n~2I) (Table I). 
358 patients (8.1 %) were diagnosed with heart failure from 1991 to 1997 in the 
ROPHAPRO-database. Data on prescribed medication by the GP was available in 309 
of these patients. Most patients (286) received a diuretic (93%) ofwltich 204 received a 
loop-diuretic, 159 (51%) received an ACE-inhibitor, 6 (2%) received a combination-
dmg of ACE-inltibitor and diuretic and 125 (40%) received digoxin. 169 (47%) ofthese 
heart failure patients were referred to a cardiologist. 
Table 1: Referral rate and dntg prescription in patients with heart failure in general practice. 
Management 
Referral; 
Cardiologist 
Internist 
Drug prescription; 
Loop diuretic 
Thiazide 
ACE-inhibitor 
Digoxin 
Discussion 
1987 - 1988 
(n~21O) 
Nom bel' (%) 
45 (21%) 
21 (10%) 
21 (10%) 
162 (77%) 
90 (43%) 
48 (23%) 
7 (3%) 
54 (16%) 
1991 - 1997 
(n~358) 
Number(%) 
169 (47%) 
152 (43%) 
309 
204 (66%) 
82 (27%) 
59 (51%) 
25 (40%) 
Tltis study shows that the incidence of heart failure as diagnosed in general practice is 
high and increases sharply with age in both men and women. In 1987-88 almost all 
incident cases were prescribed medication (notably loop diuretics, seldom ACE-
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inhibition) and only 21% was referred to a specialist. In 1991-1997 about 50% of the 
heart failure patients received ACE-inhibition, and 47% was referred to a cardiologist. 
Our specific incidence estimates are comparable to the findings of the fourth national 
study from the UK, but somewhat lower than those reported from two other Dutch 
studies.5.6.12 The differences might be due to different definitions of heart failure and 
different study populations. An increase in the incidence with advancing age in both 
men and women, is a consistent finding in all studies. 
It should be emphasised that the diagnosis of heart failure in tIus study was 
based on the clinical judgement of the GP. The clinical diagnosis of patients with heart 
failure is difficult, especially ia a primary care setting. 13·15 Although our method closely 
reflects day-to-day clinical practice, a diagnosis based on history taking and physical 
examination could lead to both underestimation (notably non-recognition of early stages 
of the syndrome) and overestimation (for example, diagnosing COPD as heart failure). 
To more reliably assess the incidence of the syndrome. ideally, each person with signs 
and symptoms suggestive of heart failure should undergo a complete comprehensive 
cardiovascular work-up. This approach is used in the Hillingdon Heart Failure Study 
and in a similar study by our own group (chapter 5).'5.'6 Comparison with findings from 
the Hillingdon study shows that the incidence of heart failure as diagnosed by GPs is an 
overestimation of the 'true incidence'. This emphasises the need to optimize early 
recoglution of heart failure in general practice. Both the number of false-positive 
diagnoses and non-recognized heart failure patients may be reduced by increasing the 
diagnostic possibilities of GPs through open access echocardiography or determination 
of neurohumoral parameters, notably brain natriuretic peptide, 15, 17,18 
Only a small proportion of the patients diagnosed with heart failure in the 
1987-88 population received an ACE-inllibitor. This is understandable since ACE-
inhibitors were introduced not long before 1988 and major trials showing the effect of 
ACE inhibitors in heart failure patients were published in the 90s.4.19.20 Our finding that 
currently about 50% of the Dutch heart failure patients receives an ACE-inhibitor may 
indicate that the management of heart failure is improving,21 
In 1988, the year of the NIVEL study, only a minority of the heart failure 
patients was referred to a specialist. The ROHAPRO-database showed that currently 
about 50% of the heart failure patients were referred to a cardiologist. Several recent 
clinical guidelines advice to refer all heart failure patients for diagnostic evaluation 
(notably echocardiography) to establish the diagnosis and determine the possible 
etiology.22-24 It is noteworthy that the current two Dutch guidelines are not consistent in 
their advice which patient to refer to a specialist for a diagnostic work-up.25.26 
Consensus on Hlls point is required to guide current practice. 
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In conclusion, the incidence rate of heart failure in general practice is high and 
clearly increases with age in both men and women. In contrast to most current clinical 
guidelines only a minority of the heart failure patients is referred to a specialist and only 
half of the patients with heart failure receives ACE-inhibition. These findings call for 
increased interest in diagnosis and management of heart failure in general practice. 
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Introduction 
The importance of heart failure as a cause for morbidity and mortality is increasingly recognised, but data on its epidemiology, and notably the incidence of the 
syndrome are scarce,l One of the reasons of the lack of epidemiologic data on heart 
failure is the difficulty of diagnosing early stages of heart failure and the virtual absence 
of target cohort studies. In the Netherlands and in the UK most heart failure patients are 
detected and treated in general practice. Heart failure is difficult to diagnose by the 
general practitioner due to the unavailability of more sophisticated or invasive 
diagnostic tools and is primarily based on clinical judgement. Heart failure carries a 
rather poor prognosis, notwithstanding the current available treatment options, therefore 
it is important to identity determinants of the development of heart failure, to enable 
targeting of effective preventive strategies. Based on data collected in the mid eighties 
jn Western societies, hypertension, coronary heart disease and diabetes mellitus appear 
to be among the major risk factors for heart failure, but, more research is needed to 
identify additional etiologic factors. 
We studied the incidence of heart failure in the Netherlands between February 
1996 and December 1997. In addition, we determined the risk factors for incident heart 
failure in the elderly. 
Methods 
Study population 
This study forms part of the Rotterdam Study, a population-based prospective cohort 
study on prevalence, incidence and determinants of chronic disabling diseases in the 
elderly. Rationale and design of the Rotterdam Study were described in detail 
elsewhere2 In short, all 10,275 inhabitants of Ommoord, a suburb of Rotterdam, who 
were 55 years or older were invited to participate. In total, 7,983 (78%) agreed to 
participate and signed informed consent. Between 1990 and 1993 all subjects were 
interviewed at home and invited to visit the research centre twice for clinical 
measurements. The data collected at baseline included history, lise of medication, 
height, weight, blood pressure levels, electrocardiography (ECG) and serum cholesterol 
sampling. 
Subjects were categorized in groups of current smokers, former smokers and 
those who never smoked. The number of pack-year exposure was calculated by the 
average daily number of cigarettes divided by 20 and multiplied with the number of 
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years smoked. Alcohol consumption was calculated from beverage specific infonnation 
obtained by a semiquantitative food frequency questioillmire. One drink was considered 
approximately equivalent to 10 grams of alcohol. Body mass index was calculated as 
weight/length' in kg/n,'. Blood pressure was calculated as the mean of two consecutive 
measurements with a random~zero sphygmomanometer. Hypertension was defmed as 
systolic blood pressure above 160 mmHg or diastolic blood pressure above 95 lmnHg or 
use of antihypertensive medication for the indication hypertension. Diabetes mellitus 
was defined as a non-fasting blood glucose above 11.0 mmoUI or the current use of an 
antidiabetic drug.3 All electrocardiograms were digitally stored and analysed using the 
MEANS program. History of myocardial infarction (MI) was defined as self-reported 
MI confirmed by a physician, or MI on the ECG.4 Electrocardiographic T axes were 
computed, applying methods that have been described in detail elsewhere.5 The ECG 
was also used to determine the presence of atrial fibrillation and left ventricular 
hypertrophy. Presence of angina pectoris was diagnosed using the Ros~ questionnaire.6 
Ankle-arm index (AAl), used as a measure of peripheral atherosclerosis, was calculated 
as the ratio of the systolic blood pressure level at the ankle and the arm. Peripheral 
arterial disease (PAD) was considered present when the AAI was lower than 0.90 at at 
least one leg. Serum total cholesterol and high density lipoprotein (HDL) cholesterol 
were determined with an automated enzymatic procedure.7 
Table 1: Rotterdam Heart Failure score 
History 
• Rest dyspnoea 
• Orthopnoea 
• Paroxysmal nocturnal dyspnoea 
• Dyspnoea on walking on level 
• Dyspnoea on climbing 
• Paroxysmal nocturnal cough 
Past history 
• Myocardial infarction 
• Hypertension 
• Angina pectoris 
• CABO or PTCA 
• Atrial fibrillation 
• Heart valve disease 
• Peripheral arterial disease 
Points 
4 
4 
3 
2 
2 
I 
Physical examination 
• Heart rate 90·110 beats/min 
> 110 beats/min 
• Raised jugular venous pressure (JVP) 
• Raised NP & hepatomegaly or edema 
• Third heart sound I gallop rhythm 
• Crepitations 
• Rhonchi 
basilar 
> basilar 
If score ~ 3, the patient was referred for 
diagnostic work·up. 
Points 
I 
2 
2 
3 
3 
I 
2 
3 
Of the 7,983 participants of the Rotterdam Study we excluded 597 participants 
because they were diagnosed as prevalent cases of heart failure. Prevalent cases were 
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defined as participants who were diagnosed with heart failure based OIl a classification 
of heart failure at the baseline examinations in 1990- I 993, or participants who 
developed heart failure during the follow-up period thereafter till I -2- I 996 (the data of 
the initiation of our incidence study). The follow-up procedures of the Rotterdam Study 
and the procedures for the classification of heart failure at baseline were described in 
detail elsewhere. 8,9 Furthermore, 979 participants of the remaining cohort at risk for 
heart failure died before the start of the incidence study. For logistic reasons we 
included only participants who were enlisted with 18 general practitioners working in 
Onulloord. Tills resulted in a cohort of 5281 participants free from heart failure in 
February 1996. 
Table 2: Baseline characteristics of the 5253 subjects at risk for heart failure and in those WiOl and 
without incident heart failure during the follow-up period. * 
Total Heart failure during 
population [ollow-up 
Characteristics Yes No p-valuet 
(11"5253) (11"127) (""5126) 
Age (years) 68.4 74.6 68.2 <0.0001 
Sex (% female) 62 56 62 <0.005 
Diabetes mellihls (%) 7 13 06 <0.05 
Hypertension (%) 26 41 26 <0.005 
Peripheral arterial disease (%) 15 34 14 <0.005 
History ofMI (%) 10 22 10 <0.005 
Angina pectoris (%) 8 13 8 0.41 
He.:1rt rate (/min) 69.8 70.1 69.8 0.87 
Atrial fibrillation (%) 2 4 2 0.99 
BeG LVH (%) 2 3 2 0.95 
T-axis (%) 
Borderline 17 26 16 0.10 
Abnonnal 7 20 7 <0.05 
Body mass index (kglm2) 26.4 27.6 26.3 <0.005 
Smokers (%) 
Current 23 24 23 0.13 
Former 40 41 40 0.90 
Alcohol intake (glday) 10.0 9.4 10.0 0.76 
Cholesterol (mmol!l) 6.67 6.42 6.68 0.38 
HDL cholesterol (nunoln) 1.36 1.27 1.36 0.08 
Total cholesterollHDL ratio 5.24 5.43 5.23 0.13 
Fibrinogen (gil) 2.74 3.02 2.73 <0.05 
Use ofCOPD medication (%) 5 7 5 0.16 
MI=myocardial infarction; L VH=left ventricular hypertrophy; COPD=chronic obstructive pulmonary 
disease. *' values are proportions or means. t comparison ofbehreen those with and without heart failure 
during follow-up, adjusted for age and sex when appropriate. 
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Case-finding 
Three methods (rapid-access diagnostic work-up, identification by computerised 
registries of the GPs and pharmacy data) were used to identiJY possible new cases of 
heart failure. The aim was to include all possible cases of heart failure emerging from 
the cohort during the follow-up period. 
Table 3: Age- and sex-specific incidence rates (per 1000 person-years, with 95% confidence intervals) in 
a general Dutch population, aged 55 years or over (the Rotterdam Study, 1996-1997) 
Age- Women (n=3258) Men (n~1995) Total (n~5253) 
group 
(years) Pyrs N Rate 95%CI Pyrs N Rate 95%CI Pyrs N Rate 95%CI 
57-64 1092 2 1.8 0.2-6.6 786 2 2.5 0.3-9.2 1878 4 2.1 0.6-5.5 
65-74 2351 14 6.0 3.3-10.0 169t 25 14.8 9.6-21.8 4042 39 9.6 6.9-13.2 
75-84 1843 24 13.0 8.3-t9.4 969 21 21.7 13.4-33.1 2812 45 16.0 11.7-21.4 
85+ 711 31 43.8 29.6-61.9 187 8 42.8 18.5-84.3 898 39 43.4 30.9-59.4 
Total 5997 7t 11.8 9.2-14.9 3633 56 15.4 11.6-20.0 9630 127 13.2 11.0-15.7 
Rapid-access diagnostic work-lip 
As part of the study, the 18 participating general practitioners (GPs) were trained in the 
application of a heart failure score. The Rotterdam Heart Failure Score (table 1) 
included signs, symptoms and medical history of a patient based on the "Boston criteria 
for heart failure" scoring system,tO \Ve added several criteria, based on review of the 
literature, to increase sensitivity for case finding as much as possible. During the study 
period, the GPs were asked to determine the Heart Failure score in all Rotterdam Study 
participants presenting with dyspnoea, progressive fatigue/anorexia of possible cardiac 
origin, paroxysmal nocturnal cough, leg oedema and nocturia and any other patient 
suspected by the OP of having heart failure. Patients who scored 3 or more points and 
any other patient suspected by the GP of heart failure were referred for a diagnostic 
work-up at the research centre, preferably before therapeutic interventions were 
initiated. A low threshold for referral was chosen to minimize non-referral of potential 
cases and to assure a high sensitivity for case finding. A high specificity was judged to 
be irrelevant in view of the aim of the study. 
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" Table 4a: Risk factors for heart failure. 
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Risk factor Adjusted Total population Age <70 Age >=70 Men Women 
for HR(95% Cl) HR (95% Cl) HR(95%Cl) HR (95% Cl) HR (95% Cl) 
Age (years) 1.09 (1.07-1.12) 1.15 (1.06-1.24) 1.10 (1.06-1.14) 1.06 (1.03-1.1 0) 1.11 (1.08-1.14) 
Sex (female) 0.57 (0.40-0.82) 0.34 (0.18-0.64) 0.76 (0.48-1.21) 
History 
Diabetes mellitus 1 1.81 (1.08-3.20) 1.51 (0.54-4.25) 1.88 (1.04-3.39) 2.06 (0.98-4.37) 1.60 (0.80-3.22) 
1-4 1.61 (0.96-2.70) 1.14 (0.39-3.32) 1.70 (0.93-3.08) 2.03 (0.95-4.34) 1.36 (0.67-2.76) 
Hypertension 1 1.76 (122-2.55) 1.28 (0.63-2.57) 2.00 (1.28-3.11) 0.97 (0.51-1.85) 2.60 (1.60-422) 
1,3,5 1.62 (1.11-2.36) 1.12 (0.55-2.31) 1.87 (1.19-2.96) 0.85 (0.44-1.64) 2.43 (1.47-4.04) 
Peripheral arterial disease 1 2.09 (1.37-3.20) 3.14 (1.50-6.57) 1.68 (1.00-2.80) 2.30 (1.19-4.45) 1.88 (1.07-329) 
1,2,5-8 1.94 (1.25-2.99) 2.92 (1.37-6.25) 1.55 (0.92-2.63) 2.15 (1.09-4.27) 1.65 (0.94-2.90) 
History afM! 1 1.83 (1.15-2.93) 2.45 (1.17-5.12) 1.51 (0.82-2.78) 1.91 (1.01-3.66) 1.80 (0.91-3.54) 
1,2,4,5 1.74 (1.09-2.78) 2.20 (1.04-4.68) 1.47 (0.80-2.71) 1.81 (0.94-3.47) 1.62 (0.82-3.21) 
Angina pectoris 1 1.25 (0.74-2.13) 1.34 (0.48-3.78) 1.24 (0.67-2.30) 125 (0.56-2.79) 1.31 (0.65-2.64) 
~ 
" ECG measures ~ 
" 
Heart rate (/min) 1 1.00 (0.99-1.01) 0.99 (0.97-1.02) 1.00 (0.99-1.02) 1.00 (0.98-1.02) 1.00 (0.98-1.02) 
" Atrial fibrillation 1 1.02 (0.37-2.81) 5.87 (1.39-24.74) 0.59 (0.14-2.43) 1.53 (0.46-5.08) 0.64 (0.09-4.62) 
" ~ 1,2,4,5,9 1.01 (0.36-2.79) 5.40 (1.20-24.31) 0.60 (0.15-2.48) 1.41 (0.41-4.84) 0.62 (0.08-4.50) 
~ ECGLVH 1 I.l7 (0.37-3.72) 3.88 (0.92-16.3) 0.48 (0.07-3.49) 1.62 (0.39-6.70) 0.76 (0.10-5.51) ;;;. Borderline T -axis 1 1.84 (1.14-2.94) 3.03 (1.41-6.50) 1.31 (0.72-2.40) 2.58 (1.27-5.08) 1.37 (0.72-2.63) 
"" 
"" 
1-3,5,9-11 1.68 (1.05-2.72) 2.75 (1.26-6.03) 1.25 (0.68-2.30) 2.30 (I.l3-4.68) 1.28 (0.67-2.46) 
~ Abnormal T-axis 1 2.70 (1.60-4.55) 4.58 (1.80-11.68) 2.14 (1.15-3.99) 3.06 (1.39-6.76) 2.50 (124-5.04) 
~ 1-3,5,9-11 2.23 (1.30-3.83) 3.52 (1.29-9.58) 1.91 (1.01-3.60) 2.64 (I.l3-6.18) 2.23 (I.l0-4.52) 
"'-. l=Age and (if applicable) sex. 2=Hypertension, 3=Body mass index, 4=ECG LVH, 5=Diabetes, 6=SmokIDg, 7=Aicohol, 8=CholesteroVHDL ratio, 9= 
'" '" History afM!, 10=Cholesterol, 11 =HDL cholesterol. The hazard ratios are given adjusted for age and gender and additionally for other potential confounders. §. 
"" ::: ~ ~ 
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Table 4b: Risk factors for heart failure (continued). 
Risk factor Adjusted Total population Age <70 Age >=70 Men Women 
for HR(9S%CI) HR (95% Cl) HR(9S%CI) HR(9S%CI) HR (95% Cl) 
Body mass index (kglm2) 1.04 (1.02-1.06) 1.04 (1.01-1.06) 1.06 (1.00-1.12) 1.03 (1.00-1.06) 1.07 (1.01-1.13) 
1,2,5 1.04 (1.01-1.06) 1.04 (1.01-1.06) 1.05 (0.99-1.11) 1.03 (1.00-1.07) 1.05 (0.99-1.11) 
Smokers 
Present 1 1.49 (0.88-2.51) 1.70 (0.66-4.40) 1.32 (0.66-2.65) 1.53 (0.52-4.48) 1.44 (0.70-2.96) 
Former 1 1.18 (0.74-1.89) 1.05 (0.40-2.74) 1.31 (0.76-225) 1.10 (0.39-3.11) 1.34 (0.77-2.33) 
Alcohol Wday) 1 1.00 (0.98-1.01) 1.00 (0.99-1.02) 0.98 (0.96-1.01) 1.01 (0.99-1.02) 0.87 (0.79-0.96) 
Cholesterol (mm01l1) 1 0.91 (0.78-1.07) 0.83 (0.63-1.11) 0.94 (0.77-1.15) 0.87 (0.68-1.12) 0.94 (0.76-1.16) 
HDL cholesterol (mmolfl) 1 0.63 (0.35-1.14) 0.20 (0.06-0.64) 1.05 (0.53-2.10) 029 (0.10-0.84) 0.97 (0.48-1.93) 
1-3.5 0.73 (0.41-1.31) 0.22 (0.07-0.72) 123 (0.62-2.46) 0.32 (0.11-0.93) 1.14 (0.57-2.28) 
CholesteroliHDL ratio 1 1.07 (0.96-1.19) 1.18 (1.02-1.38) 0.98 (0.84-1.14) 1.11 (0.95-1.29) 1.02 (0.87-1.20) 
1~3,5 1.04 (0.93-1.16) 1.17 (1.00-1.36) 0.95 (0.81-1.11) 1.10 (0.94-1.29) 0.99 (0.84-1.16) 
Fibrinogen WI) 1 1.46 (1.05-2.02) 1.57 (0.80-3.06) 1.38 (0.94-2.04) 1.14 (0.66-1.97) 1.81 (1.15-2.85) 
1,6 1.43 (1.03-1.99) 1.49 (0.74-3.03) 1.37 (0.92-2.02) 1.10 (0.63-1.94) 1.78 (1.12-2.83) 
Use of COPD medication 1.58 (0.80-3.13) 2.51 (0.98-6.42) 1.14 (0.41-3.13) 0.80 (0.25-2.56) 320 (1.37-7.43) 
1=Age and (if applicable) sex, 2=Hypertension, 3=Body mass index, 4=ECG LVH, 5=Diabetes, 6=Smoking, 7=Alcohol, 8=CholesterollHDL ratio, 9= 
History of MI, lO=Cholesterol, 11 =HDL cholesterol. The hazard ratios are given adjusted for age and gender and additionally for other potential 
confounders. 
~ 
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At the research centre, the diagnostic work-up included a standard interview and 
physical examination, chest X-ray, pulmonary function test (Le. forced expiratory 
volume in one second (FEV I), vital capacity (VC) and peak expiratory flow rate 
(PEF)), ECG, echo-Doppler cardiography, symptom-limited exercise test with 
V01NC02 determination, 6 minute walk test, haemoglobin measurement, thyroid 
function test, and pre- and post-exercise determinations of plasma neurohormone 
concentrations (Le. atrial natriuretic peptide ANP, N-terminal ANP, arginine 
vasopressin, aldosterone, renin and norepinephrine). The chest X-rays were frontal 
views and were evaluated by one radiologist without knowledge of any other diagnostic 
information. All referred patients were followed for an additional 6 months and 
important clinical findings (including results from other diagnostic tests, medication use 
and letters from medical specialists) were collected. 
Compllterised registries oJthe GP and pharmacy data 
Other potential cases of heart failure were identified through computerised registries of 
the general practitioners (including hospital discharge records) and the pharmacy 
operating in the area. The GPs classify every diagnosis according to the Intemational 
Classification of Primary Care (ICPC). By searching for every patient with the code for 
heart failure (K77) we were able to identify additional possible cases of incident heart 
failure. Through the pharmacy data we identified all possible cases by selecting all new 
prescriptions for diuretics, digoxin, ACE-inhibitors, and intravenously administrated 
loop diuretics. At the GPs office all available infonnation on the possible cases, 
detected by means of computerised GP and pharmacy registries, e.g indication for 
prescription, diagnostic tests, and letters from medical specialists, was scrutinised. As in 
the cases detected at the diagnostic work-up, an additional follow-up period of six 
months, was included. 
Case definition 
The definite classification of heart failure was determined during consensus meetings 
involving a cardiologist, internist, general practitioners and clinical epidemiologist 
reviewing all available information. Diagnosis of heart failure was based on consensus, 
using the guidelines for the diagnosis of heart failure of the Task Force on Heart Failure 
of the European Society of Cardiology (co-existence of symptoms and objective proof 
of systolic or diastolic ventricular dysfunction) complemented with information on the 
response to therapy for heart failure, if available from the patient's medical records. I I 
The members of the panel could classifY each reviewed case as; no, possible or definite 
heart failure. If all members agreed upon "no" or "definite" heart failure the case was 
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classified as such. In case of disagreement the panel tried to reach consensus. If no 
consensus was reached the case was classified as "possible" heart failure. In case of 
possible or definite heart failure the panel could also add a remark to the classification. 
The remark was made when the panel had little more additional infomlation than the 
history and physical examination of the general practitioner, the response to therapy if 
present and the clinical diagnosis of the GP to establish a final panel diagnosis. In these 
cases, no objective measurements of ventricular function were available. Furthermore, 
the panel had to detenlline the starting date of heart failure. In the analyses of the 
present study emphasis is 011 cases classified as definite incident cases of heart failure. 
Data analysis 
Excluded from the cohort of 5281 Rotterdam Study participants free from heart failure 
at the initiation of the incidence study, were 28 persons who were lost to follow-up 
because they moved out of the area and could not be traced back. Age- and gender-
specific incidence rates of heart failure per 10 year age-groups were calculated by 
dividing the number of definite incident heart failure cases by the number of person-
years at risk, calculated by the sum of each participant's contribution of follow-up time 
per age-band. Our follow-up period started at 1-2-1996 and ended either at the onset of 
heart failure, at death or at the end of the follow-up period, 31-12-1997. Exact 95% 
confidence Intervals (95%CI) were calculated using Poisson standard errors. 
Difference in baseline characteristics between participants with and without 
incident heart failure were examined using logistic regression analyses, adjusting for 
age and sex when appropriate. Cox' proportional hazards regression analysis was used 
to identify potential risk factors for heart failure. We separately adjusted each risk factor 
for potential confounders. The adjustment for potential confounders was based on 
pathofysiologic knowledge and prior studies. Subgroup analyses were perfoffiled to 
examine whether age (above and below the median age of70 years) or gender modified 
the association between the potential risk h1ctors and the occurrence of heart failure. To 
minimize the effect of missing data in the multivariate analysis, missing values of 
categorical variables were replaced by dummies. Missing values of continuous variables 
were replaced by the mean and a dununy was added to the mode1. 12 All data analyses 
were perfoffiled using the SPSS statistical package 7.5.2, except for the calculation of 
the 95% CI of the incidence rates where the STATA statistical package release 5.0 was 
used. 
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Figure 1: Number of cases detected by each of the three search strategies. 
Results 
Incidence of heart failure 
Baseline characteristics of the 5253 participants included in tius study are presented in 
table 2. During the follow-up period of 23 months, 127 definite new cases of heart 
failure were identified; 56 men and 71 women. In total 145 persons were referred for a 
diagnostic work-up and 40 of them were incident cases of heart failure. The remahung 
87 incident cases were identified through the computerised registries and patient files 
(including hospital letters) oflhe general practitioners and the pharmacy data (figure 1). 
The age- and sex-specific incidence is given in table 3. The overall incidence rate of 
"deficite" heart failure was 13.2 per 1000 person-years (95%CI 11.0-15.7); 15.4 
(95%CI 1l.6-20.0) in men and 11.8 (95%CI 9.2-14.9) in women. For "possible" 
incident heart failure these estimates were 17.2 (95%CI 14.7-20.0), 19.3 (95%CI 15.1-
24.4) and 15.9 (95%CI 12.9-19.4), respectively. Figure 2 compares our age-specific 
incidences with those reported from a similar study in Hillingdon, London. 13 Figure 3 
shows the age-specific incidences of possible and definite heart failure. 
Riskfactors for heart failure 
Table 2 shows baseline characteristics of the participants who did and did not develop 
heart failure during the follow-up period. Subjects with incident heart failure were older, 
had a higher body mass index and fibrinogen level, more often had a low ankle-arm 
incidence and risk Jactors of hear' failure 
58 Chapter 5 
blood pressure index (an indicator of peripheral arterial disease) or a history of a MI and 
were more often hypertensive or diabetic. 
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FJgure 2: Estimated age- and sex-specific annual incidence rates of heart failure in the London 
Hillingdoll Study and in the Rotterdam Study. 
Hislory 
Diabetes, hypertension, peripheral arterial disease and prior myocardial infarction were 
independent risk factors for heart failure, and almost doubled the risk. The age- and sex-
adjusted hazard ratios (HR) were 1.81 [95% CI 1.08-3.20], 1.76 [1.22-2.55],2.09 [1.37-
3.20] and 1.83 [1.15-2.93], respectively (table 4). Similar associations were found for 
the participants above and below the age of 70 years and for men and women. For 
hypertension, however, the risks appeared to be higher in women (HR 2.60 [1.60-4.22]) 
and for peripheral arterial disease the risk was most pronounced in those younger than 
70 years of age. 
ECG measures 
Atrial fibrillation increased the risk for heart failure considerably (BR 5.87 [1.36-
24.18]), but only in subjects younger than 70 years of age. 
Participants with a borderline or an abnormal T-axis had a marked increased 
risk for heart failure (HR 1.84 [1.14-2.94] and 2.70 [1.60-4.55]). Electrocardiographic 
left ventricular hypertrophy (L VB) on ECG and heart rate were not associated with an 
increased risk of incident heart failure in our study. 
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Body mass index, smoking, and alcohol 
Body mass index was associated with the risk for heart failure (HR 1.04 [1.02-1.06]). 
Additional adjustment for diabetes and hypertension did not change the risk estimates. 
Compared to never smokers, the risk of heart failure was not increased among current 
smokers who had a smoking history of20 pack-years or less, but the risk was increased 
(HR 1.84 [1.01-3.34]) for those with more than 20 pack-years. Alcohol use was not 
clearly related to the occurrence of heart failure. 
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Figure 3: Estimated age-specific incidence rates of defInite and probable & definite incident heart failure 
in the Rotterdam Study 
Cholesterol, HDL cholesterol andjibrinogen 
No relationship between cholesterol and incident heart failure was observed. Higher 
HDL cholesterol levels seemed to diminish the risk for heart failure, notably in men 
(HR 0.29 [0.10-0.84]) and those aged younger than 70 years of age (HR 0.20 [0.06-
0.64]). Similarly, a higher cholesterollHDL cholesterol ratio increased the risk, notably 
in the younger age group (HR 1.18 [1.02-1.38]). In addition higher fibrinogen levels 
were associated with a higher risk for heart failure (HR 1.46 [1.05-2.02]). Adjustment 
for smoking did not influence these findings 
COPD 
The risk of heart failure for subjects who used COPD medication was increased in 
women only HR 3.20 [1.37-7.43]. 
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Discussion 
Our study shows that the incidence of heart failure increases sharply with age in both 
men and women. The overall incidence rate of heart failure was estimated at 13.2 per 
1000 person-years in the general population of men and women aged 55 years and over. 
Age, male gender, higher body mass index, history of MI, diabetes, hypertension, 
peripheral arterial disease, electrocardiographic T axis abnormalities and higher 
fibrinogen levels are risk factors for heart failure. Atrial fibrillation and the use of 
COPD medication are related to heart failure in, respectively, subjects younger than 70 
years of age and women only. 
Our study population was recmited directly from the general population and 
therefore provides a representative sample to assess the incidence estimates in the 
population at large. However, it should be emphasized that in spite of the low initial 
non-response rate of the baseline population (22%), it is likely that the more healthy 
subjects participated. Therefore, the "tme" incidence in the population at large may 
even be somewhat higher. 14,15 
The strength of our study lies in the highly sensitive case finding of the 
possible incident cases. Through the computerised registries and patient files of the 
general practitioners and the pharmacy operating in the area in combination with our 
rapid access clinic we were able not only to find the cases with full blown heart failure 
presented to hospitals but also the mild cases and the very old who may not be send to a 
specialist. Through the general practitioners records we were able to follow the potential 
cases through time, to take the response to therapy into account and to observe whether 
additional new signs, symptoms or other clinical findings occurred. 
Since there is no "gold standard" for the diagnosis of heart failure we used a 
multidisciplinary diagnostic panel to assess the diagnosis, using the guidelines for the 
diagnosis of heart failure of the Task Force on Heart Failure of the ESC, supplemented 
with response to therapy for heart failure as the best possible diagnostic too!. I I This was 
also done in the Hillingdon Heart Failure Study. 13 Using the strict case definition of the 
ESC may, however, have led to non-recognition of very mild cases of heart failure and 
therefor may have led to underestimation of the rates. If we combine cases classified as 
possible heart failure with the definite cases, the incidence estimates increased by 
approximately 30%. 
Although there is similarity with the methods of our study, the Hillingdon 
Heart Failure Study recently reported estimates that were lower in all age groups.13 
There is no a-priori reason why incidence rates in the London area would be lower than 
in Rotterdam. Rather, the difference might be explained by differences in case finding. 
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In the Hillingdon Heart Failure study new cases of heart failure were identified from 
hospital admissions and through a daily rapid access oulpatient heart failure clinic to 
which GPs referred all new cases of suspected heart failure. As a consequence the cases 
diagnosed by the GP and not referred to Ihe hospilal, possibly because Ihey were 10 old 
or to weak to be referred, may have been missed. Moreover cases being treated by the 
internist and also some outpatient cases treated for other cardiac problems by 
cardiologists who developed heart failure are likely to have been missed. FurthemlOre, 
in contrast to the Hillingdon study, we trained the participating GPs to use a diagnostic 
screening tool with maximized sensitivity to assure referral of even cases with dubious 
presentation and very mild symptoms. Finally, we do not think that the differences in 
observed incidence rates could be explained by a difference in degree of certainty in 
establishing a diagnosis of heart failure. In view of the amount of diagnostic 
information and clinical data, this seems unlikely. Even in the 34 definite cases detected 
by the pharmacy database detailed letters from cardiologists and from internists were 
available in respectively 53% and 12% of the cases in additional to information from 
the GP. In 35% of these cases echocardiographic data were available. 
Risk factors for the development of heart failure in the population at large have 
been examined in the late eighties in the Study of Men Born in 1913 and in the 
Framingham Heart Study and might have changed over the years. 16.18 These studies 
used a relatively crude heart failure score to establish the diagnosis of heart failure. 
Nowadays morc objective measurements of cardiac function, such as echocardiography 
are available enhancing the accuracy ofllCart failure detection. 
Framinghanl reported diabetes to be a powerful risk factor especially in women 
and in the younger age group.18 We also found that diabetes is a risk factor for heart 
failure, the risk however being higher at older age. 
Hypertension is known to be a marked risk factor for heart failure, more clearly 
so in men and in younger patients.l6,18 OUf study confirms the strong association of 
hypertension with heart failure risk. Left ventricular hypertrophy was the most 
pronounced risk factor in the Framingham Study, particularly in the younger patient 
group. The risk associated with LVH on ECG and the risk for heart failure was 
strongest in younger subjects in our study, but the association was not statistically 
significant. A possible explanation is that over the years the prevalence of LVH among 
subjects with heart failure decreased. 19 
To our knowledge, this is the first study to report that a borderline and 
abnormal T axis are associated with the development of heart failure. This provides 
further support for the view that the T axis is a solid general marker for subclinical 
myocardial damage.5 
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Interestingly, the use of COPD medication was associated with the incidence of 
heart failure, in particular in women. This might be attributable to the difficulty of 
diagnosing heart failure (which could lead to (mis)treatment with COPD medication) or 
to the fact that heart failure and COPD often coincide. 
We conclude that the incidence of heart failure in an older population is high 
and exponentially increases with age in both men and women. Peripheral arterial 
disease, electrocardiographic T axis abnormalities, diabetes, hypertension, high body 
mass index and atrial fibrillation (the latter only in men younger then 70 years of age) 
are independent risk factors for the occurrence of heart failure. 
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Introduction 
The diagnosis of heart failure is fraught with difficulties and a challenging task. TIlls particularly applies to primary care, where the diagnosis of heart failure is mainly 
based on clinical judgement of the general practitioner (GP). Prior studies showed that 
the validity of the clinical diagnosis of heart failure is limited, particularly in women, 
the obese and the elderly. 1-3 
Incorrect diagnosis has major consequences for both patients and health services. 
Therefore, methods to improve early recognition of heart failure are required. 
The diagnostic work-up in patients with clinically suspected heart failure by 
general practitioners consists of patient history and physical examination, possibly 
followed by electrocardiography (ECG) and chest X-ray. Additional diagnostic tests 
sometimes ordered by GPs include pulmonary function test, exercise test and 
haemoglobin and thyroid function determination. Currently, echocardiography is 
considered to be the key noninvasive diagnostic test in the diagnosis of heart failure. In 
the Netherlands, as in other some countries, patients have to be referred to a cardiologist 
for echo cardiography. More recently, neurohormones e.g. atrial natriuretic peptide 
(ANP) and brain natriuretic peptide (BNP), have been proposed as possible diagnostic 
indicators for heart failure. 3.S To our knowledge, studies comparing different diagnostic 
strategies in patients suspected of heart failure, including assessment of the (added) 
value of signs and symptoms, EeG, chest X-ray or neurohormones are lacking. To 
address tlus issue, we performed a study in a cohort of 5281 men and women aged 57 
years or older. 
Methods 
This study forms part of the Rotterdam Study, a population-based prospective cohort 
study on prevalence, incidence and deternuuants of ChrOlUC disabling diseases in the 
elderly. Rationale and design of the Rotterdam Study were described in detail 
elsewhere.6 In short, all 10,275 inhabitants of Ommoord, a suburb of Rotterdam, who 
were 55 years or older were invited to participate. In total, 7,983 (78%) agreed to 
participate and signed informed consent. Of the 7,983 participants of the Rotterdam 
Study we excluded 612 participants because they were already diagnosed as cases of 
heart failure. 
Furthermore, 979 participants of the remaining cohort died before February 
1996, the starting point of the present study. For logistic reasons we included only 
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participants who were enlisted with the 18 general practitioners working in the 
Ommoord area. This resulted in a cohort of 5266 participants. 
Table 1: Rotterdam Heart Failure score 
History 
• Rest dyspnoea 
• Orthopnoea 
• Paroxysmal noetumal dyspnoea 
• Dyspnoea on walking on level 
• Dyspnoea on climbing 
• Paroxysmal nocturnal cough 
Past history 
• Myocardial infarction 
• Hypertension 
• Angina pectoris 
• CABG or PTCA 
• Atrial fibrillation 
• Heart valve disease 
• Peripheral arterial disease 
Diagnostic work-up 
Points 
4 
4 
3 
2 
2 
I 
I 
Physical examination 
• Heart rate 90-110 beats/min 
> 110 beats/min 
• Raisedjugular venous pressure (JVP) 
• Raised JVP & hepatomegaly or edema 
• Third heart sound I gallop rhythm 
• Crepitations 
• Rhonchi 
basilar 
> basilar 
If score 2: 3, the patient was referred for 
diagnostic work-up. 
Points 
I 
2 
2 
3 
3 
2 
3 
We aimed to detect as many subjects suspected of heart failure as possible. Therefore, 
the 18 participating general practitioners were lrained in the application of a heart 
failure score. The Rotterdam Heart Failure Score (table I) was based on signs, 
symptoms and history of a patient corresponding with the UBoston criteria for heart 
failure" scoring system.1 Several criteria (notably, history of: myocardial infarction, 
hypertension, angina pectoris, coronary artery bypass graft (CABO) or percutaneous 
transluminal angioplasty (PTCA), atrial fibrillation, heart valve disease and peripheral 
arterial disease) were added, based on review of the literature, to enhance referral of all 
subjects with possible heart failure. During the sludy period, the OPs were asked to 
determine the Heart Failure score in all Rotterdam Study participants presenting wiIh 
dyspnoea, progressive fatigue/anorexia of possible cardiac origin, paroxysmal nocturnal 
cough, leg oedema and nocturia or any other reason for suspicion of heart failure. All 
Rotterdam Study participanls who scored 3 or more poinls and those suspected by the 
OP of heart failure for other reasons were referred for a diagnostic work-up at the 
research centre before hospital referral and preferably before therapeutic interventions 
were initiated. A low threshold for referral was chosen to minimize non-referral of 
potential cases and to assure inclusion of all heart failure cases. 
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Table 2a: Characteristics at presentation of patients suspected of heart failure classified according to the 
eventual diagnosis of presence or absence of heart failure, Values are proportions (%) unless stated 
otherwise. 
Heart Failure present Heart Failure absent p·value 
(n~44) (n~105) 
Mean age (years) 78.8 75.7 <0.02 
Women 45 67 < 0.02 
Patient history 
Rest dyspnea 25 24 0.88 
Orthopnea 32 16 0.04 
Paroxysmal nocturnal dyspnea 34 15 O,ol 
Dyspnea on exertion 77 74 0.70 
Nocturnal cough 27 28 0.97 
Cough 23 31 0.29 
Wheezing 34 42 0.37 
Nocturia 34 27 0.36 
Swollen legs 59 48 0.20 
History of COPD 27 35 0.35 
Hypertension 52 51 0.93 
Diabetes 14 10 0.58 
History ofMJ 18 9 0.10 
CABG 5 3 0.60 
PTCA 2 3 0.84 
Hypercholesterolemia 7 12 0.32 
After referral to the research centre, the diagnostic work-up included a standard 
interview and physical examination, chest X-ray, pulmonary ftmction test (i.e. forced 
expiratory volume in one second (FEYI), vital capacity (YC) and peak expiratory flow 
rate (PEF)), electrocardiogram (ECG), echo-Doppler cardiography, cardiopulmonary 
exercise testing, 6 minute walk test, haemoglobin measureinent, thyroid function test, 
and pre- and post-exercise blood sampling for measurement of plasma neurohomlOnes 
(i.e. atrial natriuretic peptide (ANP), N-terminal ANP (NT-ANP), brain natriuretic 
peptide (BNP), arginine vasopressin (A YP), aldosterone, renin, norepinephrine (NE) 
and semicarbazide-sensitive amine oxidase (SSAO)). 
Myocardial infarction (MI), chronic obstructive pulmonary disease (COPD), 
hypertension, diabetes, CABG, PTCA and hypercholestrerolemia were considered to be 
present if self reported by the participant or if reported by the referring GP. Jugular 
venous pressure was determined by the method described by Borst.s Posteroanterior 
chest X-rays were interpreted by one and the same radiologist without knowledge of 
any other diagnostic infonnation. Thoracic and cardiac diameters were measured to 
calculate the cardiothoracic (CT) ratio. The chest radiograph was considered indicative 
for heart failure if it showed pleural effusion, redistribution, interstitial pulmonary 
Diagnosis ill patients suspected of heartfailure: imparlance o!neurollOrmones 
70 Chapter 6 
Table 2b: Clinical characteristics of patients suspected of heart failure classified according to the 
eventual diagnosis of presence or absence of heart failure. Values are proportions (%) unless stated 
otherwise. 
Heart Failure present Heart Failure absent p-value 
(n~44) (n~105) 
Phxsical examination 
Jugular venous pressure 
Increased 21 10 0.07 
Unable to measure 25 25 0.98 
S, 5 2 0.38 
S, 0 2 0.73 
Crepitations 64 30 <0.0001 
Rhonchi 11 8 0.46 
Edema 5 38 0.18 
Hepatomegaly 
Present 9 7 0.61 
Missing 9 10 0.93 
Chest X-ray 
CT-ratio 0.53 0.49 <0.001 
Pleural effusion 14 0 0.58 
Redistribution 7 0 0.70 
Interstitial pulmonary edema 7 0 0.70 
Alveolar pulmonary edema 0 0 
Evidence of CO PO 18 10 0.15 
ECG 
Atrial fibrillation 30 I <0.001 
Pacemaker rhythm 2 I 0.54 
Left bundle branch block 5 3 0.60 
Right bundle branch block (RBBB) 11 6 0.24 
Incomplete RBBB 9 8 0.88 
Left anterior fascicular block 7 3 0.28 
Left posterior fascicular block 0 1 0.81 
Intra ventricular conduction defect 0 I 0.81 
Left ventricular hypertrophy 16 1 0.006 
Right ventricular hypertrophy 2 1 0.54 
AnteriorMI 16 8 0.13 
Inferior MI 1 3 0.12 
ST-segment elevation (Stel) 2 0 0.75 
ST-segmenl depression (Stdp) 0 0 
Repolarization disturbances II 0.02 
Neurohonllones (means) 
ANP (pglml) 517 227 < 0.0001 
NT-ANP (nmoVI) 1.17 0.47 < 0.0001 
BNP(pglml) 178 55 <0.0001 
NE (pglml) 485 357 0.002 
SSAO(mU~) 608 424 < 0.0001 
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edema or alveolar pulmonary edema. Furthermore, evidence of COPD was registered by 
the radiologist. ECGs were stored digitally and analyzed by the Modular ECG Analysis 
System (MEANS).9 In case the MEANS program could not interpret an ECG the 
research physician evaluated it. 
Table 3a: Results of tile diagnostic models to assess the presence of heart failure in patients suspected of 
heart failure. 
Diagnostic History History + History + History + 
model Physical Physical + Physical + 
Chest X-ray Chest X-ray + 
ECG 
{model A) (model B) (model C) (model D) 
Detenninant Coeff. (SE) OR Coeff. (SE) OR Coeff. (SE) OR Coeff. (SE) OR 
History 
Constant -7.67 (2.36) ·6.48 (2.41) -11.78 (3.00) -12.52 (3.50) 
Age (per year) 0.09 (0.03) 1.1 0.07 (0.03) 1.1 0.Q3 (0.03) 1.0 0.05 (0.04) 1.1 
Sex (female) -0.97 (0.42) 0.4 -0.83 (0.43) 0.4 -1.43 (0.50) 0.2 -1.72 (0.59) 0.2 
Orthopnea 1.62 (0.53) 5.1 1.65 (0.54) 5.2 1.75 (0.59) 5.7 2.08 (0.72) 8.0 
History ofMI 1.06 (0.60) 2.9 0.96 (0.61) 2.6 0.63 (0.66) 1.9 0.83 (0.79) 2.3 
History of -0.93 (0.49) 0.4 -0.94 (0.50) 0.4 -0.87 (0.53) 0.4 -1.1 3 (0.67) 0.3 
COPD 
Physical 
examination 
Crepitations 1.09 (0.43) 3.0 1.28 (0.47) 3.6 1.38 (0.56) 4.0 
Chest X-ray 
CT ratio 0.17 (0.04) 1.2 0.14 (0.05) 1.2 
ECG 
Atrial 4.61 (1.27) 100.8 
fibrillation 
REP 2.45 (1.32) 11.5 
Coeff. = regression coefficient estimated from the multivariate model; SE = standard error; OR = odds 
ratio; CT ratio = cardiothoracic ratio; REP = repolarization disturbances 
All referred patients were followed for an additional 6 months and important 
clinical findings (including results from other diagnostic tests, medication use and 
letters from medical specialists) were collected. 
Blood sampling and neurohormone analysis 
Venous blood was collected in a 10ml syringe after the participant had been supine 
during an ECG recording and echocardiographic investigation for at least 20 minutes. 
The blood from the syringe was immediately injected into prechilled tubes. Blood for 
measurement of ANP, NT-ANP and BNP was collected in 10-ml tubes containing 
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EDT A (l9mg) and aprotinin (1 OOOkIU), while for SSAO and NE measurements blood 
was collected in heparinized 10-n11 tubes containing 12 mg of glutathione. The tubes 
were placed on ice and centrifuged within 30 minutes from sampling (4°C, 10 min, 
3000 x g). Plasma was stored in polyethylene tubes at -20°C at the research centre 
before transportation to and storage at the Cardiovascular Research Laboratory, 
Erasmus University Medical Center, where the plasma was stored at -sooe until 
analyses. Plasma NE was determined by high-performance liquid chromatography with 
fluorimetric detection.lO Plasma SSAO was measured as described previously. I I 
Commercially available radioimmunoassay kits were used for measurement of ANP 
(Nichols Institute, Wijchen, The Netherlands), NT-ANP (Biotop, Oulu, Finland) and 
BNP (Peninsula, Belmont, CA, USA). 
Table 3b: Results of the diagnostic models to assess the presence of heart failure in patients suspected of 
heart failure. 
Diagnostic model History + History + 
Physical + Physical + 
ECG NT-ANP 
(model E) (model F) 
Determinant CoefI (SE) OR Coelf. (SE) OR 
History 
Constant -8.83 (3.05) -5.92 (3.09) 
Age (per year) 0.09 (0.04) 1.1 0.02 (0.04) 1.0 
Sex (female) -1.19 (0.53) 0.3 -1.06 (0.57) 0.3 
Orthopnea 1.40 (0.71) 4.1 1.52 (0.74) 4.6 
History ofMI 1.01 (0.72) 2.8 0.21 (0.84) 1.2 
History of COPD -0.78 (0.61) 0.5 -0.67 (0.66) 0.5 
Physical examination 
Crepitations 1.28 (0.53) 3.6 1.62 (0.60) 5.0 
ECG 
Atrial fibrillation 4.68 (1.15) 108.0 
LVH 3.10 (1.24) 22.3 
Neurohormol1es 
NT-ANP 4.33 (0.81) 76.3 
Coefl'. = regression coefficient estimated [rom the Illultivariate model; SE = standard error; OR = odds 
ratio 
Case definition 
The presence of heart failure was determined six months after the initial visit during 
consensus meetings by an expert panel involving a cardiologist, internist, general 
practitioners and clinical epidemiologist reviewing all available information, except for 
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the neurohormones BNP and SSAO. During the consensus meetings data on these 
neurohormones were not yet available. Diagnosis of heart failure was based on 
consensus, using the guidelines for the diagnosis of heart failure of the Task Force on 
Heart Failure of the European Society of Cardiology (co-existence of symptoms and 
objective proof of systolic or diastolic ventricular dysfimction) complemented with any 
information on the response to therapy for heart failure during a six months follow-up 
period, extracted from the patient's medical records, 12 The members of the panel could 
classifY each reviewed case as: no, possible or definite heart failure. If all members 
agreed upon "no" or "definite' heart failure the case was classified as such. In case of 
disagreement the panel tried to reach consensus. If no consensus was reached the case 
was classified as "possible" heart failure. In case of possible or definite heart failure the 
panel could also add a remark to the classification. The remark was made when the 
panel had little more additional infonnation than the history and physical examination 
of the general practitioner, the response to therapy if present and the clinical diagnosis 
of the OP to establish a final panel diagnosis. In these cases, no objective measurements 
of ventricular function were available. In the analyses of the present study emphasis is 
on participants classified as definite cases of heart failure. 
Data analysis 
The association between each diagnostic variable and the presence of heart failure was 
first quantified using univariable logistic regression analysis. Variables that were 
associated with the presence or absence of heart failure (defined as a p-value <; 0.20) 
were included in a multi variable logistic regression model to determine their 
independent contribution to the prediction of heart failure. In this multi variable analysis 
different diagnostic strategies were considered, following the order in which diagnostic 
work-up of patients suspected of heart failure is commonly carried out in practice. As 
this work up always starts with a patient's history, we initially included all univariably 
associated variables from patient history in an overall multivariate model. 
Of tlus model we first evaluated its goodness of fit (reliability) using the Hosmer 
& Lemeshow method. 13 If this reliability was classified as satisfactory (defined as p-
value> 0.20) , the Receiver Operating Characteristic (ROC) area and its standard error 
were estimated. 14•15 The ROC area provides an estimate of the overall diagnostic or 
discriminative value of the model (i.e. ability to discriminate between patients with and 
without heart failure) and can range from 0.5 (no diagnostic information) to 1.0 (perfect 
discrimination). A value over 0.7 can be interpreted as reasonable and over 0.8 as 
good. 16 Subsequently, model reduction was performed by excluding variables (one by 
one) from the overall lustory model until all of the remaining regression coefficients 
Diagnosis in patients suspected of heart failure: importance o!llew'o!JormoJles 
74 Chapter 6 
differed "significantly" from zero (defined as a p-value < 0.10). Each of the excluded 
variables as well as the univariate non-significant variables were then re-entered in the 
model to evaluate whether they yielded a higher ROC area. The ROC area of each 
reduced model was compared with the overall model, by estimating the differences in 
ROC area with 95% C1.17,18 This approach yielded a reduced history model with a 
minimum number of detenninants that did not have a statistically significant lower 
ROC area than the overall history model. 
The ROC area reflects the overall value of a model and does not directly indicate 
the clinical value (Le. ability of mling in or out the disease) of a model. Therefore, we 
also estimated and compared the positive predictive value (PPY) (Le. proportion of 
patients with a positive test result that was correctly diagnosed) and the negative 
predictive value (NPY) (Le. the proportion of patients with a negative test result that 
was correctly diagnosed) obtained by the different reduced history models. In advance 
we decided that our threshold probabilities to calculate and compare the PPY and NPY 
were < 0.20 and >0.50. Less than 0.20 was chosen because we believe that this 
threshold reflects routine clinical practice to the extend that a subject classified with less 
than 20% probability of heart failure will not be treated or referred to a specialist by a 
GP. The upper threshold of 50% was chosen because we believe that in practice, a 
subject with more than 50 % probability of having heart failure is likely to be treated as 
such by the GP. Finally, the model with the highest ROC area as well as the best 
classification of patients with and without heart failure (assuming the 20% and 50% 
thresholds) was considered to be the "most effective" history model. 
To assess the value of physical examination in addition to the information 
obtained from the patient history, the same approach of model reduction and 
comparison was applied to all univariably significant (p-value ,; 0.20) physical 
examination items after they were added to the final patient history model. This yielded 
a reduced history and physical examination model. 
Similarly, the (univariably) significant findings from chest X-ray, ECG, and 
neurohormone assessment were consecutively added (one by one) to the history and 
physical examination model in various different orders. 
Of all 149 subjects, 8 participants had missing values on one or more 
neurohormones. To decrease bias and increase statistical efficiency these missing 
neurohormone values were imputed using the expectation-maximization (EM) 
method. 19,2o Such imputation is based on correlation between each variable with 
missing values and all other variables. These correlations were estimated from the 141 
set of complete subjects. All data analyses were performed using the SPSS statistical 
package 7.5.2. 
Diagnosis in patients slispected of heart failure: imporlance oflleurohormones 
Chapter 6 75 
Table 4: The distributions of subjects with and without heart 'failure according to the probability 
estimated by the different diagnostic models. 
Histo!)' [AJ History & Physical examination fBJ 
Estimated HF Total HF+ HF- HF Total HF+ HF-
Probabili~t %* n (%) N(%) n(%) %* n (%) n ~%) n(%) 
~O.IO 4 24 (16) I (2) 23(22) 4 26 (17) I (2) 25 (24) 
0.10-0.20 23 30 (20) 7 (16) 23 (22) 13 38 (26) 5 (II) 33 (31) 
0.20-0.50 31 74 (50) 23 (52) 51 (49) 36 58 (39) 21 (48) 37 (35) 
0.50-0.60 56 9 (6) 5 (II) 4 (4) 54 13 (9) 7 (16) 6 (6) 
;0, 0.60 67 12 (8) 8 (18) 4 (4) 71 14 (9) 10 (23) 4 (4) 
All 149 44 105 149 44 105 
Histo!), & Physical & X-ray [C] History & Physical & X-ray & EeG [DJ 
Estimated HF Total HF+ HF- HF Total HF+ HF-
Probabili!y %* n(%) N(%) n (%) %* 11 (%) n(%) 11 (%) 
S; 0.10 2 47 (32) I (2) 46 (44) 3 59 (40) 2 (5) 57 (54) 
0.10-0.20 18 22 (15) 4 (9) 18 (17) 17 24 (16) 4 (9) 20 (19) 
0.20-0.50 31 45 (30) 14 (32) 31 (30) 31 29 (20) 9 (21) 20 (19) 
0.50-0.60 70 10 (7) 7 (16) 3 (3) 64 II (7) 7 (16) 4 (4) 
, 0.60 n 25 (18) 18 (41) 7 (7) 85 26 (17) 22 (50) 4 (4) 
All 149 44 105 149 44 105 
History' & Physical & EeG [E] History & Physical & NT-ANP [F] 
Estimated HF Total HF+ fIF- HF Total HF+ HF-
Probabili~y %* 11 (%) N(%) n (%) %* n (%) 11 (%) n(%) 
,; 0.10 3 61 (41) 2 (5) 59 (56) 3 68 (46) 2 (5) 66 (63) 
0.10-0.20 32 19 (13) 6 (14) 13 (12) 20 20 (13) 4 (9) 16 (15) 
0.20-0.50 22 36 (24) 8 (18) 28 (27) 29 21 (14) 6 (14) 15 (14) 
0.50-0.60 100 5 (3) 5 (II) 0 50 8 (5) 4 (9) 4 (4) 
, 0.60 82 28 (19) 23 (52) 5 (5) 88 32 (22) 28 (64) 4 (4) 
All 149 44 105 149 44 105 
HF == heart failure; + = present; - = absent; HFlfo* = observed prevalence (probability) of HF in that 
category of estimated probability. 
Results 
During the follow-up period of 30 months, 149 participants were referred to the research 
center for a diagnostic work-up. 40% was male and the age range was 61- 92 years. Of 
the 149 participants, 44 (29.5%) were classified during the consensus meetings as 
definite cases of heart failure. 
Table 2a shows the associations between various patient history and clinical 
characteristics at presentation and the presence Of absence of heart failure. Presence of 
heart failure was related to age, gender, orthopnea, paroxysmal nocturnal dyspnea, 
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edema and history of myocardial infarction (p-value ,; 0.20). Table 2b shows these 
associations for the characteristics obtained from physical examination, ECG, chest x-
ray and neurohormone detenninatiolls. 
The overall model including all univariably associated (p ,; 0.20) history 
variables had a ROC area of 0.78 (SE: 0.042). After model reduction and re-entering of 
excluded variables the rednced history model (model A) inclnded age, gender, 
orthopnea, history of myocardial infarction and history of COPD (ROC area 0.75, SE: 
0.045; fig 1 and table 3). Excluding more variables from this model significantly 
reduced the ROC area. Table 4 shows the actual observed prevalence of heart failnre 
and the corresponding numbers of patients across the selected ranges of probability 
estimated by the derived models. Model A selected 21 subjects with a probability > 
50% of which 13 actually had heart failnre leading to a PPV of 0.62 (table 5). It also 
selected 54 subjects with a probability,; 0.20 of which 46 had no heart failnre leading to 
a NPV of 0.85. 
Table 5. The estimated receiver operating characteristic (ROC) area and the positive and negative 
predictive values defined as, respectively, the prevalence of heart failure when the model predicts a 
probability of >50% (positive predictive value: PPV) and the absence of heart failure when the model 
predicts a probability of heart failure of <20% (negative predictive value: NPV). 
Model ROC area (SE) PPV NPV 
A 0.75 (0.05) 0.62 0.85 
B 0.78 (0.04) 0.63 0.91 
C 0.84 (0.03) 0.71 0.93 
D 0.90 (0.03) 0.81 0.93 
E 0.89 (0.03) 0.85 0.90 
F 0.92 (0.02) 0.80 0.93 
ROC = Receiver Operating Characteristic; SE "" standard error; PPY :'0 positive predictive value; NPV:'O 
negative predictive value. 
Addition of the significant findings obtained during physical examination (Le. 
increased jugular venous pressure, crepitations and edema) to model A increased the 
ROC area from 0.75 to 0.79 (p~0.23). The reduced model (model B) including model A 
and crepitations only, had a similar ROC area of 0.78 (table 3; fig 1). Although addition 
of crepitations to model A did not increase the ROC area, the NPV increased from 0.85 
to 0.91 and the PPV from 0.62 to 0.63. Therefore, it was left in model B. 
Addition of the univariably significant chest X-ray findings {cardiothoracic 
(CT)-ratio and signs of COPD) to model B significantly increased the ROC area from 
0.78 to 0.84 (p~0.02). However, including CT ratio only yielded the same ROC area 
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(model C, table 3, fig. I). Tables 4 and 5 show the increase in number of correctly 
classified patients and the PPV and NPV. Subsequent addition of all (univariably 
significant) ECG findings (i.e. atrial fibrillation, LVH, anterior and inferior myocardial 
infarction and repolarization distnrbances (REP)) to model C significantly increased the 
ROC area to 0.90 (p~0.03). Excluding anterior and inferior myocardial infarction and 
LVH yielded the same ROC area (model D, table 3, fig. I). Finally, separate addition of 
each of the neurohormones ANP, NT-ANP, BNP, SSAO and NE further increased the 
ROC area of model D to 0.93 (SE 0.023, p~0.08), 0.93 (SE 0.022, p~0.07), 0.92 (SE 
0.024, p~0.18), 0.93 (SE 0.022; p~0.08) and 0.91 (SE 0,025, p~0.46), respectively. 
Adding ECG findings before the chest X-ray to the most efficient history and 
physical examination model (model B), yielded a ROC area of 0.90 (SE 0.032; 
p~0.002). After reduction, the model (model E) including Model B, atrial fibrillation 
and LVH yielded a ROC area of 0.89 (SE 0.029) (table 3, fig. I). Addition of the 
significant chest X-ray findings did not clearly change the ROC are, 0.90 (SE 0.025, 
p~O.1 0) and the positive and negative predictive values remained similar for both 
models (data not shown). Finally, the addition of one of the neurohormones ANP, NT-
ANP, BNP or SSAO increased the ROC area to 0.93 (SE 0.023; p~O.OI), 0.94 (SE 
0.022; P~O.OI), 0.92 (SE 0.024; p~0.02) and 0.92 (SE 0.023; p~0.04), respectively. 
The diagnostic model E (including history, physical examination and ECG 
findings) had a similar area under the ROC curve (0.89) as the diagnostic models 
including history, physical examination (model B) and only one of the neurohormones 
(ANP, NT-ANP, BNP, SSAO (ROC area between 0.87 and 0.92; p > 0.10). The 
diagnostic model including model Band NT-ANP (model F) had a slightly lower PPV 
(0.80) compared to model E (0.85), with a slightly higher NPV (0.93 vs 0.90)(table 5). 
Discussion 
Our results show that addition of neurohonnones to the information obtained during 
history taking and physical examination is as effective as the more conventional 
approaches (using information from chest X-ray and ECG) in determining the presence 
of heart failure in patients suspected of heart failure. 
In the assessment of the diagnostic value of each diagnostic test ill patients 
suspected of heart failure we evaluated each test according to the chronological order 
commonly applied in clinical practice. The added value of each test was evaluated 
conditional on the results of previous diagnostic tests. As far as we know no other 
stndies in heart failure have so far used this approach. The few published studies 
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evaluating the usefulness of natriuretic peptides, studied these as a single tool for 
detecting left ventricular dysfunction or heart failure.3,4 
Neurohomtones 
BNP SSAO ANP NT·ANP 
Figure 1: Flowchart for different diagnostic strategies and the corresponding ROC areas. The numbers in 
the circles indicate the ROC area. 
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Of the history variables, only age, gender, orthopnoe, history of myocardial 
infarction and history of COPD were independent determinants of the presence of heart 
failure. Except for crepitations, physical examination did not have additional diagnostic 
value. This is probably due to mutual dependency. The information already obtained 
during history taking largely overlaps the diagnostic infomlation obtained from the 
physical examination. Furthermore, the information obtained from a chest X-ray does 
not appear to add to the diagnostic efficiency when an electrocardiogram is available. 
Since there is no "gold standard" for the diagnosis of heart failure we used a 
multidisciplinary expert panel to classify the cases, using the guidelines for the 
diagnosis of heart failure of the Task Force on Heart Failure of the European Society of 
Cardiology, and adding the response to therapy for heart failure.'2. When studying the 
diagnostic value of tests, the gold standard or 'true' diagnosis should preferably be 
independent from the test results that are to be studied.21 Since there is no gold standard 
independent of the studied tests available for heart failure, this unavoidably leads to 
incorporation bias.22 The incorporation bias might lead to overestimation of the 
diagnostics performance of test. However, none of the incorporated tests is perfectly 
related to heart failure and the classification of the panel is currently the best reference 
test. FurthemlOre, BNP and SSAO were not used in the classification procedure for 
heart failure but showed almost the same diagnostic results as ANP and NT-ANP. 
Therefore, we think incorporation bias did not materially influence our findings. 
Although echocardiography currently is the most appropriate diagnostic tool to 
assess the diagnosis of heart failure we did not incorporate it in our diagnostic models, 
since echocardiography is not a readily available diagnostic tool for the general 
practitioner. Furthermore as our final diagnosis of heart failure was largely dependent 
on the demonstration of cardiac dysfunction by echocardiography, including 
echocardiography in the diagnostic models would have led to serious incorporation bias. 
Subjects included in this study were a selected group of subjects suspected of 
heart failure. Most subjects with (full-blown) acute heart failure were not sent to the 
research center but were admitted to the hospital. This does not affect our findings 
because also in routine primary care these patients would not have had extensive 
additional testing .. 
We arbitrarily chose probability thresholds to estimate positive and negative 
predictive values. Obviously, one could use other thresholds leading to other predictive 
values based on personal preferences. Proper definition of such thresholds, however, 
requires information about acceptable costs related to these incorrect classifications. 
Not only the diagnostic value of the neurohormones in important, but also the 
feasibility (that is handling and stability of the sample and the rapidness, price and 
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simplicity) of the measurement in clinical routine. Is has been shown that BNP and NT-
ANP are stable in whole blood.23•25 Furthermore, they can be measured with a rapid aud 
simple test at a low price (€ 23). 
Our findings suggest that measurement of natriuretic peptides might be useful in 
routine clinical (general) practice as a diagnostic tool to assess the presence of heart 
failure in patients suspected of heart failure, particularly as an alternative to 
electrocardiography. The use of natriuretic peptides may reduce the number of 
misdiagnoses, mistreatment an unnecessary referral to cardiologists and thereby 
increase cost-effectiveness. 
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Introduction 
The transition of acute to more chronic fonns of cardiac disease in the Western World is Ulmlistakable. l;1 The increase in hospitalization rates for heart failure, in the 
Netherlands as well as elsewhere in Europe, is a visible consequence of this transition.3 
Although recent papers have described the prevalence of heart failure and left ventricular 
systolic dysfimction as well as the incidence of heart failure,4-7 recent infonnation on the 
prognosis of heart failure in the general population is limited.8,9 
We set out to detennine the prognosis and cause of death in participants of the 
large population-based Rotterdam Study who were found to have heart failure at the 
baseline examinations. 
Methods 
Sludy populalion 
The present investigation is part of the Rotterdam Study, a population-based cohort study 
aimed at assessing the occurrence of and risk factors for chronic disease in the elderly. 
Objectives and methods of the Rotterdam Study have been described in detail elsewhere. 10 
Briefly, in the Rotterdam Study all men and women aged 55 years or older, living in the 
Ommoord district of Rotterdam, were invitated to participate. Of the 10275 eligible 
subjects, 7983 (78%) agreed to participate and signed infonned consent. Participants were 
interviewed at home and subsequently examined at the research centre. The Rotterdam 
Study was approved by the Medical Ethics Conllnittee of Erasmus University Medical 
School. From 1990 to 1993 baseline data were collected, including established 
cardiovascular risk factors, use of medications, history of cardiovascular disease, 
symptoms and signs attributable to heart failure and an electrocardiogram (ECG). 
Hypertension was defined as systolic blood pressure above 160 nlln Hg or diastolic 
blood pressure above 95 mm Hg or the use of antihypertensive medication for the 
indication hypertension. Diabetes mellitus was defined as a non-fasting blood glucose 
above 11.1 nmlOVl or use of antidiabetic medication. Presence of angina pectoris and 
shortness of breath was assessed by means of the Rose and WHO questionnaires. ll 
Shortness of breath was defined as WHO grade I or higher dyspnoea, reflecting shortness 
of breath at rest or on moderate exertion. Drug use was coded according to the Anatomical 
Therapeutic Chemical (ATC) classification index. Cockcroft's fonnula was used to 
estimate creatinine clearance. 12 
The prognosis of heart failure in the general population. The Rotterdam Study 
86 Chapter 7 
Table I: Baseline characteristics of all participants and according to the presence of heart failure. 
Characteristic All No Heart Failure Heart Failure p' (n~5255) (n~5074) (n~181) 
Age (years) 68.9 (8.6) 68.6 (8.4) 77.3 (8.0) <0.001 
Female sex 59.3% 59.2% 60.2% 0.69 
Height (em) 167.0 (9) 167.0 (9) 165.0 (9) 0.53 
Weight (kg) 73.0 (12) 73.0 (12) 73.0 (12) 0.Q7 
Body mass index (kglm2) 26.4 (3.7) 26.3 (3.7) 26.9 (4.2) 0.Q7 
Heart rate (beats/min) 74.0 (12) 74.0 (12) 72.0 (12) 0.27 
Blood pressure (nun Hg) 
Systolic 139.0 (22) 139.0 (22) 139.0 (26) 0.001 
Diastolic 74.0 (12) 74.0 (12) 69.0 (12) <0.001 
Total cholesteroUHDL ratio 5.3 (1.6) 5.2.0 (1.6) 5.7 (1.9) <0.001 
CUrrent smoking 22.9% 23.1% 16.1% 0.69 
Hypertension 30,5% 30.2% 40.3% 0.24 
Diabetes 10.6% 10.2% 21.8% 0.01 
Myocardial infarction 11.1% 9.6% 52.5% <0.001 
Atrial fibrillation 3.4% 1.8% 23.8% <0.001 
History of angina pectoris 7.1% 6.0% 38.9% <0.001 
History of PTCA 0.9% 0.7% 5.6% <0.001 
History ofCABG 2.4% 2.1% 12,9% <0.001 
Use of cardiovascular medication 36.2% 34.2% 92.7% <0.001 
Serum sodium (mmol/liter) 140.0 (3) 140.0 (3) 139.0 (4) 0.Q2 
Serum potassium (nmlOllliler) 4.1 (0.3) 4.1 (0.3) 4.1 (0.4) 0.09 
Serum urea (mmolliiter) 6.3 (1.9) 6.2 (18) 8.0 (3.2) <0.001 
Serum creatinine (nunollliter) 83.0 (18) 82.0 (17) 98.0 (34) <0.001 
Creatinine clearance (mllmin) 73.0 (21) 73.0 (20) 57.0 (18) <0.001 
Values are mean values ± SD unless otherwise indicated. 
P value for difference between participants with and without heart failure, adjusted for differences in age. 
A 12-lead resting ECG was recorded using an ACTA electrocardiograph 
(ESAOTE Biomedica, Florence, Italy). All electrocardiograms were digitally stored and 
analysed using the Modular ECG Analysis System (MEANS) program, a standardised and 
validated ECG software program,13 to assess the presence of atrial fibrillation, myocardial 
infarction, and left ventricular hypertrophy. hl addition, if participants reported a history of 
myocardial infarction without electrocardiographic evidence at the time of examination, 
myocardial infarction was deemed present, provided that evidence of myocardial infarction 
was found in the patients' records (including hospital discharge letters). 
Echocardiography was perfonned with the participant in the partial left decubitus 
position (Toshiba SSH-60A). 2-Dimensional inlaging using parasternal long-axis views 
was perfonned to aid M-mode studies. Measuremenls were made according to the 
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recommendations of the American Society of Echocardiography using a leading edge to 
leading edge convention. Left ventricular intemal dinaension (L VJDed) was measured at 
end diastole, as defined by the onset of the QRS complex and at end systole (LVJDes), as 
determined at the nadir of septal motion. The percentage fractional shortening was 
calculated as 100[(LVIDed - LVIDes)/LVIDed) and used as an index of systolic function. 
Impaired left ventricular function was deemed to be present if fractional shortening was 
less than or equal to 25%, corresponding to a left ventricular ejection fraction of 42.5%.14 
Table 2: Number of events and incidence rates according to the presence or absence of heart failure. 
Endpoint No Heart Failure Heart Failure 
(n~5074) (n~181) 
Events Rate (95% CI) per Events Rate (95% CI) per 
1000 person-years 1000 person-years 
4 year follow-up 
Non-fatal cardiac event 167 8.3 (7.1· 9.6) 12 19.9 (10.3- 34.8) 
Cardiac death 121 6.0 (5.0- 7.2) 30 49.7 (33.6- 71.0) 
Sudden cardiac death 51 2.5 (1.9- 3.3) 15 24.9 (13.9- 41.0) 
All-cause mortality 416 20.6 (18.7-22.7) 55 91.1 (68.7-118.7) 
6 year follow-up 
All-cause mortality 711 24.4 (22.7-26.3) 85 104.6 (83.6-129.4) 
Classification o[heart [ailllre 
The prevalence of heart failure in the Rotterdam Study has been described in detail 
elsewhere.6 A two-step approach was used to assess the presence of heart failure. Firstly, 
the presence of shortness of breath at rest or on exertion,15 ankle edema and pulmonary 
crepitations was determined. If at least two of these were present in combination with 
evidence of cardiac disease (angina pectoris. myocardial infarction, documented coronary 
artery bypass surgery, documented percutaneous transluminal angioplasty, atrial 
fibrillation or electrocardiographic left ventricular hypertrophy), while shortness of breath 
could not be attributed to chronic obstructive pubnonary disease Cas indicated by use of 
chronic obstructive pulmonary disease medication -ATC code r03), heart failure was 
considered present. This combination had a sensitivity of 80% to detect and a specificity of 
98% to exclude the presence of definite heart failure as detemlined by a cardiologist on 
clinical grounds in a validation study. 16 
Secondly, the examining physician used standardised questions to verifY the 
indication of cardiovascular medication with the participant. In case diuretics, glycosides 
or angiotensin converting enzyme inhibitors were used, a possible indication of heart 
The prognosis of heart/ai/lire ill Ihe general population. The Rotterdam Study 
88 Chapter 7 
failure (as opposed to hypertension, arrhythmias etc.) was verified. Only participants with 
a definite indication for heart failure, in whom objective evidence of cardiac disease was 
fmmd, were included. 
As infonnation on shortness of breath and indications for cardiovascular 
medication use was not obtained in the begitming of the Rotterdam Study, prevalence 
estimates are based on 5540 participants (age 68.9 ± 8.7 years, 2251 men). 
Table 3: Hazard ratios (95% confidence intervals) for non-fatal cardiac events and death associated with 
heart failure. 
Endpoint 
4 year follow-up 
Non-fatal cardiac event 
Cardiac death 
Sudden cardiac death 
Total mortality 
6 year follow-up 
Total mortality 
All 
Crude Age adjusted 
2.8 (1.5-5.0) 2.6 (1.4 - 4.7) 
8.8 (5.9 - 13.2) 4.0 (2.6 - 6.0) 
10.8 (6.0 - 19) 4.8 (2.6 - 8.7) 
4.5 (3.4 - 6.0) 2.1 (1.6-2.8) 
4.4 (3.5 - 5.5) 2.1 (1.8 - 2.7) 
Men 
Crude Age adjusted 
1.6 (0.7 -4.0) 1.5 (0.6·3.8) 
6.6 (3.6 - 12.0) 3.7 (2.0·6.7) 
6.8 (3.0 - 15.3) 3.7 (1.6·8.5) 
3.4 (2.1 - 5.3) 2.0 (1.2-3.1) 
4.2 (3.0·5.8) 2.4 (1.7-3.3) 
Endpoint Women 
4 year follow-up 
Non-fatal cardiac event 
Cardiac death 
Sudden cardiac death 
Total mortality 
6 year follow-up 
Total mortality 
FollOW-lip 
Crude Age adjusted 
5.0 (2.3 - 10.9) 
11.5 (6.6-19.8) 
19.6 (8.3 - 46.3) 
5.7 (3.9- 8.1) 
4.7 (3.5 - 6.4) 
4.1 (1.8-9.3) 
4.3 (2.4-7.7) 
6.6 (2.6-16.5) 
2.2 (1.5-3.3) 
1.9 (1.4-2.7) 
Infonnation on vital slatus was obtained regularly from the municipal health authorities in 
Rotterdam. Further infonnation on fatal as well as non-fatal endpoints for the participants 
enlisted with the general practitioners (OPs) working in the study district of Ommoord 
(85% of the cohort) was obtained from these OPs. All participating OPs have 
computerised records, and fatal and non-fatal events of study participants are recorded on 
their computer files and sent to the Rotterdam Study data-centre regularly. In April 1996 
medical records (including infonnation available at the OP office and letters of medical 
specialists) of participants under the care ofOPs outside the Ommoord area (15% of the 
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cohort) were checked for possible events by research physicians from the Rotterdam 
Study. After notification, cause and circwnstances of the events were established by 
questionnaire from the GPs and by the research physicians scrutinising information from 
hospital discharge records. Complete follow-up infonnation was available for 95% (5255 
participants) of the study population as of April 1996 (follow-up 2.8 - 6.5 years, mean 4.1 
years). In addition, vital status ofthese 5255 persons was assessed at April I 1998 (follow-
up 4.8 - 8.5 years, mean 6.1 years). 
Classification of fatal and non-fatal events was based on the 10th revision of the 
International Classification of Diseases (ICD-IO). We defined cardiac mortality as death 
from myocardial infarction or other heart diseases (lCD-IO: 121-28, 42, 43, 46-50), or 
sudden cardiac death. Sudden cardiac death was defined as death occurring within one 
hour after onset of symptoms, or unwitnessed death while a cardiac cause could not be 
excluded. 17,18 Non-fatal cardiac events were defined as myocardial infarction, or 
chronic ischemic heart disease (lCD-10:121-25), coronary artery bypass surgery, or 
percutaneous transluminal coronary angioplasty. All events were classified 
independently by two research physicians. If there was disagreement, a consensus was 
reached in a separate session. Finally, aU events were verified by a medical expert in 
cardiovascular disease. If the expert disagreed with the research physicians, the expert's 
judgement was considered final. The research physicians and the experts based their 
decisions on the same data. 
Table 4: Survival in participants with congestive heart failure. 
Age-adjusted survival of participants without heart failure in parentheses. 
I year 2 years 5 years 
All 89% (97%) 79% (93%) 59% (85%) 
Men 91% (96%) 81% (92%) 56% (84%) 
Women 87% (98%) 78% (94%) 61% (86%) 
Data analysis 
Differences in baseline characteristics between participants with and without heart failure 
and between those with and without follow-up data were examined with the nnpaired 
student's T-test (continuous variables) and binomial tests (discrete variables). Logistic 
regression analysis was used to test if the differences persisted upon adjustment for age. 
95% confidence intervals for incidence rates were calculated assuming Poisson 
distribution. Cox's proportional-hazards analysis was used to detennine the risk of non-
fatal cardiac events, cardiac death, sudden cardiac death and all-cause mortality associated 
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with heart failure, taking participants without heart failure as the reference group. Kaplan-
Meier survival curves were constmcted for men and women having heart failure (figure 1), 
separately calculating survival at one, two and five years (table 4). The logrank test was 
used to test for differences in survival. All statistical tests were two sided. 
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Figure 1: Kaplan Meier Survival Curves for 72 men (74.5 ± 7.4 years) and 109 women (79.2 ± 7.8) with 
heart failure. 
Results 
Table I provides baseline characteristics of 5255 Rotterdam Study participants aged 55 -
94 years in whom the prevalence of heart failure was detennined and follow-up data were 
available. 181 participants (3.4%) were classified as having heart failure. The prevalence 
of heart failure increased with age and did not differ between men and women, as 
described in detail elsewhere.6 
The prognosis of heartfailure in 'he general population. The Rotterdam Study 
("l 
Table 5: Mortality in heart failure; results from hospital based studies, 20,21 placebo arms of2 trials in patients with heart failure24,2S and placebo arms of2 "" 
'" 
" trials in patients with asymptomatic left ventricular dysfunction.22.23 -
" ~ 
Study N Mean Women Mean Total Average Sudden Description of patients -...} 
Age (%) Follow-Up Mortality Mortality' Death 
~ (yrs.) (months) (%) (% of total 
" 
mortali!)') 
i Hospital based studies Madsen BK et a4 199420 190 66t 28% 24.5§ 60 (32%) 15,7 380 consecutive patients aged < 76 years admitted to hospital with heart failure. 190 
'0' excluded. Median EF 33%""" 
<Q, 
". 
" Croft JB et a4 1999"1 154.956 771 58% 72' 86% / 79%t 13,8 33% Medicare patients, aged >= 67 years, with §. , 80l 1st hospitaliza.tion for heart failure in ~ 1986. ::: 
"  Trials - Heart failure 'S. 
V-HeFT 11,199125 401 61 30 153 (38%) 15,2 63% Mild to moderate heart failure, NYHA II-~ III 
i SOL VD treattnen~ 199124 1284 61 20% 41 510 (40%) 11,6 22% NYHA II - m, EF < 35% 
~ Trials - Asymptomatic 
" LV dysfunction .g
~ SOLVD prevention, 199235 2117 59 11% 37 334 (16%) 5,1 31%§ No symptoms of heart failure, EF <35% SAVE, 199223 1116 60 18% 42 275 (25%) 7,0 56% No S)mptoms of heart failure, 3-16 days following myocardial infarction, EF <40% 
~ 
" 
'" 
• Average mortality (per 100 patient years): (total mortality / follow-up) x 12 months . c 
~ t Median age ~ l Men and women. respectively 
O! § Median follow-up 
!i:? Total follow-up 6 years 
it , Placebo arm ::0: hydralazine & isosorbide-dinitrate ~ 
" 
•• EF = Ejection fraction . 
;;l '" N ~ 
'" ~ Table 6: Prognosis of heart failure in population-based studies of incident heart failure. 8,9,29,30 
~ Rotterdam. Study results for comparison. ~. 
~ 
".. Study Time Mean Women Mean Total Sudden Survival (%) ~ n Average §. Span Age (%) Follow-up MOrtality Mortality' Deatht 
'is' (yrs) (months) (%) 90 days I yr. 2 yr. 5 yr. 
~ Framingham Heart Study 652 1948- 57±8t 53 47 551 (85%) 21 50% Men 73 I-~ 57179 46 25135 S· Ho KL et al, 199329 1988 76±10§ Women 72/- 64188 56 38153 
-".. - prospective ~ 
~ 
:: Hillingdon Heart Failure Study 220 1995- 73178: 46 16 90 (41%) 31 All 71 .... 64 ~ Cowie ~ et ai, 19988 1997 
'" 
- prospective 
.g 
f Olmsted County, Minnesota 216 1991- 77±12 42 All 86 1- 76188 35 I 41 Senni M et al, 1999930 1997 
!::i 
- retrospective 
'" Rotterdam Study 181 1990- 77±8 60 73 85 (47%) 7.7 27% Men 99 91 81 56 i - prospective 1998 Women 97 87 78 61 g. 
• Average mortality (per 100 patient years): (total mortality / follow-up) x 12 months ~ 
!;:> t % oftota! mortality 
~ t 1950's § 1980's 
, Men and women, respectively , 
~ .. 1,. ; overall survival! survival in persons still alive 90 days following the diagnosis of heart failure n 
•• 6 months. '" ., 
"0 
;; 
~ 
-.J 
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Baseline characteristics of participants with (n ~ 5255) and without (n ~ 285) 
follow-up data were highly comparable, in tenns of age (68.9 vs 69.0 years; p~0.83), 
gender (59.2% vs 61.8% female gender; p~0.43) and prevalence of heart failure (3.4% 
vs 3.5%; p~I.OO). Differences in other baseline characteristics as described in table 1 
also failed to reach statistical significance. 
During the follow-up period ending April I 1996,471 (9.0%) participants died; 
151 (3.1%) died from a cardiac-related cause, 66 (43.7%) of whom died suddenly. Non-
fatal cardiac events occurred in 179 (3.7%) participants. By April 1998 an additional 
325 participants had died, leading to a total mortality of 15.1 %. Table 2 shows the 
number of events and the crude incidence rates for participants with and without heart 
failure. Participants with heart failure had an increased age-adjusted risk of death, 
including cardiac death (table 3). The risk of death in persons with heart failure did not 
change appreciably upon extension of follow-up from April 1996 to April 1998 (table 
3). The increased risk of sudden death in persons with heart failure was particularly 
striking (HR 4.8, 95% CI 2.6-8.7). In addition, persons with heart failure appear to have 
an increased risk for nOllMfatai cardiac events. 
Table 4 and figure 1 show survival in all 181 participants (72 men, mean age 75 ± 
7 years, and 109 women, mean age 79 ± 8 years) with heart failure. Survival at one, two 
and five years was in the order of 90%, 80% and 60% respectively. Although crude 
survival did not differ between men and women (P-Iogr~0.13, figure 1), age adjusted 
survival was higher in women than in men (hazard ratio 0.53, 95% C.1. 0.34 - 0.83), as 
women generally were found to have heart failure at a higher age. 
Discussion 
In tlus population-based study of 5255 persons aged 55 to 95 years the prognosis of 181 
participants having heart failure was poor; age-adjusted mortality was doubled in 
comparison to persons without heart failure and a four- to six-fold increased risk of 
sudden death was observed in persons with heart failure. 
TIle diagnosis of heart failure is fraught with difficulties. 16 In this population-based 
study we used a previously validated combination of signs and symptoms, that bears 
resemblance to the definition of heart failure proposed by the Task Force on Heart Failure 
ofthe European Society ofCardiology.6,19 Furthennore, use of medication for heart failure 
was verified as symptoms and signs may be less prominent in stable patients on heart 
failure medication. 
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The potential effect of 5% losses to follow-up, mainly due to unknown addresses, 
is difficult to assess. Differences in baseline characteristics between participants with and 
without follow-up infonnation proved to be quite small, and since a loss of 5% is quite 
low, we expect any bias as a result of losses to follow-up to be very limited. 
The advantages of our study relate to the fact that it was population-based and 
included elderly participants. In addition, extensive baseline information was obtained 
and coding of events occurring during follow-up took place in a highly standardized 
manner. 
Prognosis oJheart Jailure 
Studies of patients admitted to hospital with heart failure as well as clinical trials have 
demonstrated the poor prognosis of heart failure (table 5).20-25 Tills information, however, 
only pertains to selected groups of heart failure patients. For example, it is obvious that 
clinical trials in heart failure have predominantly enrolled men and that participants in 
these trials tend to be younger and have less comorbidity than the typical heart failure 
patient in the community. 
Information on the prognosis of heart failure in the commwlity is limited; three 
studies addressed the prognosis in persons diagnosed as having heart failure (i.e. prevalent 
heart failure, not necessarily new cases of heart failure).26-28 The Study of Men Born in 
1913 reported a five year mortality rate of 26% in men with manifest heart failure.26 
NHANES reported ten year mortality rates of 72% and 60% respectively in men and 
women aged 65 to 75 years, in whom the presence of heart failnre was assessed in 197J.27 
Lastly, the Helsinki Ageing Study found a four year mortality rate of 46% in a group of 
501 persons (aged 75 to 86 years, 377 women) of whom 41 (34 women) had heart 
failure.28 Age and gender adjusted risk for all cause mortality was 2.1 (95% CI 1.3 - 3.4) 
and 4.2 (95% CI 1.9 - 5.6) for cardiovascular mortality. Another three studies, 
characteristics of which are provided in table 6, assessed prognosis in patients with new 
onset heart failure.8.9,29,30 
It is a reasonable assumption that heart failure mortality as observed in participants 
of the Rotterdam Study reflects an optimistic estimate of the prognosis in the population, 
as mortality was assessed in participants with prevalent heart failure. Earlier population-
based studies have indicated that mortality is especially lllgh in the first three months 
following the onset of heart failure (table 6).8,9,29 It should be noted that although the 
response rate in our study was high (79%), non-response may have led to an 
overestinlation of heart failure survival as response rates were lower in higher age groups 
and as it is conceivable that persons having severe heart failure were less likely to 
participate" 
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Sudden dealh in hearl jailure 
Notwithstanding the ongoing debate on the assessment of mode of death in patients with 
heart failure,31 our findings that risk of sudden death in persons with heart failure is 
appreciable Crulllot easily be dismissed. Indeed, the Framinghrull Heart Study, the only 
population based study that has specifically addressed sudden death in heart failure, 
reported a similar fivefold increased risk for sudden deatll.32 Hence, sudden death does not 
appear to be restricted to those having more advanced heart failure. 
In conclusion, the prognosis of persons with heart failure is poor. Persons with 
heart failure have a fivefold increase in the risk for sudden death. To date the "typical" 
heart failure patient has largely been excluded from clinical trials.33 1lris should change if 
the prognosis of heart failure in the general population is to be improved.34 
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Introduction 
H eart failure is a growing health problem in western societies. The increase in the occurrence of heart failure is mainly attributable to the ageing of the population 
and improvement in prevention and treatment of cardiovascular disorders, including 
ischemic heart disease.' The prognosis of patients with heart failure is poor; within 5 
years of a diagnosis of heart failure in the Framingham Heart Study, 75% of the men 
and 62% of the women had died.2 One third to one half of all deaths in patients with 
heart failure occur sudden.3,4 
Heart failure is attributable to systolic dysfimction, diastolic dysfunction or both. 
Left ventricular systolic dysfunction is relatively common with about half of the cases 
being asymptomatic.5•6 It is known that impaired systolic function is associated with a 
poorer prognosis in patients with myocardial infarction or congestive heart failure. 
Little is known about the prognosis of left ventricular dysfunction in the population at 
large. 
The objective of this study was to determine whether left ventricular systolic 
dysfunction in the general population is associated with a higher risk for all cause 
mortality, cardiac death and sudden cardiac death. 
Methods 
This study forms part of the Rotterdam Study, a prospective follow-up study of subjects 
aged 55 years or over to investigate the prevalence, incidence, and risk factors for 
chronic disabling diseases of the elderly. The study was approved by the Medical Ethics 
Committee of the Erasmus University. Rationale and design of the Rotterdam Study 
were described in detail elsewhere.? In short, all 10,275 inhabitants of OmnlOord, a 
suburb of Rotterdam, who were 55 years or older were invited to participate. In total, 
7,983 (78%) agreed to participate and signed informed consent. Between 1990 and 1993 
all subjects were interviewed at home and invited to visit the research centre twice for 
clinical measurements. The data collected at baseline included history, height, weight, 
blood pressure levels and an electrocardiogram (ECG). For logistic reasons, 
echocardiographic facilities were not available in the beginning of the Rotterdam Study 
and in several short periods thereafter. 
Subjects were categorized in groups of current smokers, former smokers and 
those who never smoked. Body mass index was calculated as weightllength2 in kg/m2• 
Blood pressure was calculated as the mean of two consecutive measurements with a 
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random-zero sphygmomanometer. Hypertension was defined as systolic blood pressure 
above 160 mmHg or diastolic blood pressure above 95 mmHg or use of 
antihypertensive medication for the indication hypertension. Diabetes mellitus was 
defined as a non-fasting blood glucose above 11.0 nmlOUI or the current use of an 
antidiabetic dmg.8 History of myocardial infarction (MI) was defined as self-reported 
MI confirmed by a physician, or MI on the ECG.9 Presence of angina pectoris was 
diagnosed using the Rose questionnaire. 10 Senllll total cholesterol was determined with 
an automated enzymatic procedure, I I 
Table 1: Baseline characteristics of the 2823 elderly participants in the Rotterdam Study, in whom 
echocardiography was perfonned. Groups are classified according to presence or absence of a technically 
adequate echocardiographic recording allowing assessment of left ventricular systolic function (LVSF) . 
LVSF LVSF pNalue 
assessed not assessable 
(IF2270) (n~553) 
Age (years) I 65.7 (0.16) 70.2 (0.35) <0.001 
Women (%) 54.7 51.5 0.18 
Body mass index (kg/nl) t 26.0 (0.09) 26.9 (0.17) <0.001 
Hypertension (%) 25.0 32.7 0.03 
Angina pectoris (%) 8.1 10.1 0.33 
History ofM[ (%) 9.7 15.2 0.05 
Diabetes mellitus (%) 5.5 9.0 0.10 
Use ofCOPD medication (%) 3.5 6.3 0.01 
CUrrent smokers (%) 21.8 25.4 0.001 
Former smokers (%) 45.3 42.0 0.05 
Never smokers (%) 32.9 32.5 0.32 
Cholesterol (nmlOVI) t 6.6 (0.02) 6.6 (0.05) 0.45 
LVSF = left ventricular systolic function, MI = myocardial infarction, COPD = chronic obstructive 
pulmonary disease. 'Adjusted for age and gender when appropriate. t Values are means (SEM). 
. 
Echocardiography was performed with the participant in the left lateral position 
(Toshiba SSH-60A). Standard two-dimensional imaging using parasternal long axis 
views was performed to aid M-mode studies. All measurements were made according to 
the reconmlendations of the American Society of Echocardiography, using a leading 
edge to leading edge method. 12 Left ventricular internal dimension at end-diastole 
(LVlDed) was determined at the end of diastole as defined by the onset of the QRS-
complex. Left ventricular internal dimension at end-systole (LVlDes) was measured at 
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the nadir of septal motion. Left ventricular fractional shortening (FS) was calculated as 
the percentage difference between LYIDed and LYIDes: (LYIDed - LYIDes)/ LYIDed 
*100%. Fractional shortening is often used as an index of systolic function. Systolic 
function was considered to be impaired if fractional shortening was less than 25%, 
corresponding to a left ventricular ejection fraction of 42.5%.13 
In the present analysis the follow-up period of the population lasted until 
January 1996. Clinical follow-up data on fatal and non-fatal endpoints were obtained 
from the general practitioners (GPs) working in the study district of Onunoord through 
linkage of the general practitioner's automated medical record system to the data base 
of the Rotterdam Study on a regular basis. From the municipal health service in 
Rotterdam infonnation was obtained on the vital status of the participants. Study 
physicians regularly evaluated all events, including deaths, reported by the GPs by 
reviewing the medical records and hospital letters available at the GP's office. In case of 
death of a participant the GP filled in a questionnaire on the cause and circumstances of 
death of the participant. Study physicians checked follow-up data from participants with 
a GP outside the Ommoord area (15% of the cohort) by reviewing the complete patient 
chart and correspondence from medical specialists of these participants. All events were 
classified according to the International Classification of Diseases, 10th version (ICD-
10). The events were classified independently by two research physicians from the 
Rotterdam Study. In case of disagreement between the two, a consensus was sought in a 
separate session. A medical expert in the field of cardiovascular disease checked all 
classified events. If no consensus was reached, this expert's judgement was considered 
final. Cardiac mortality was defined as death from myocardial infarction, chronic 
ischemic disease, pulmonary embolism or other pulmonary heart disease, 
cardiomyopathy, cardiac arrest, arrhythmia, heart failure (all defined according to ICD-
10: I 21-28, 142-43, 146-150), or sudden cardiac death. Sudden cardiac death was 
defined as death occurring instantaneously or within one hour after onset of symptoms 
or unwitnessed death, in which a cardiac cause could not be excluded. 14,15 
Subjects living in nursing homes (n~897) were excluded from ultrasound 
examination because of teclmical limitations in the transport of the ultrasound 
equipment. Of the remaining 7,086 participants 6,494 visited the research centre. As 
mentioned before echocardiographic facilities were not available during certain periods, 
this resulted in 2,823 echocardiograms being perfonned. We excluded 553 participants 
(20%) whose echocardiographic registrations were deemed inadequate to reliably 
measure fractional shortening. Of the remaining 2,270 participants, data on the vital 
status was missing in 315 and on cause specific mortality in 318 participants. Subjects 
without follow-up data (mainly because they moved to unknown addresses or no data 
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could be gathered about the vital status or time of death) were excluded from the 
survival analyses. Overall, complete follow-up infonnation was available for 86% 
(Le.1 ,955/2,270) of the participants. 
Table 2: Characteristics of subjects with impaired· and with normal left ventricular systolic function 
(LVSF). 
Impaired LVSF NomtalLVSF p-Valuet 
(1l~73) (n~2197) 
Age (years): 68.3 (0.87) 65.6 (0.16) 0.002 
Women(%) 34.2 55.4 <0.001 
Body mass index (kg/m2) t 25.9 (0.36) 26.0 (0.09) 0.80 
Hypertension (%) 27.4 24.9 0.75 
Angina pectoris (%) 26.0 7.5 <0.001 
History ofMI (%) 30.9 8.9 <0.001 
Diabetes mellitus (%) 5.5 5.5 0.62 
Use ofCOPD medication (%) 9.6 3.3 0.01 
CUrrent smokers (%) 15.1 22.0 0.16 
Fomler smokers (%) 65.8 44.7 0.02 
Never smokers (%) 19.2 33.3 0.15 
Cholesterol (mmoVl) t 6.5 (0.13) 6.6 (0.02) 0.89 
Fractional shortening t 20.9 (0.39) 40.1 (0.15) 
LVSF = left ventricular systolic function, MI = myocardial infarction, COPD = chronic obstructive 
pulmonary disease. * impaired = fractional shortening <25%, f Adjusted for age and gender when 
appropriate. t Values are means (SEM). 
Means and proportions of baseline characteristics between subjecls with and 
without an echocardiography and between subjects with an echocardiography with a 
normal and impaired left ventricular systolic function were compared using logistic 
regression, adjusting for age and gender when appropriate. 
Kaplan-Meier survival curves were plotted to describe the trend in mortality 
over time for subjects with nonnal and impaired left ventricular systolic function. 
Differences between the curves were compared with the logrank test. 
The risk for alI-cause dealh, cardiac death or sudden death associated with 
impaired fractional shortening was calculated using Cox' proportional hazards model, 
and presented with a 95% confidence interval (95% CI). To adjust for age and gender, 
these were added to the model (model A). Next, adjustments were made for other 
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prognostic factors such as body mass index, diabetes mellitus, use of COPD medication, 
smoking and cholesterol level and these were added to a subsequent model (model B). 
Finally, cardiovascular risk factors potentially included in the causal pathway of left 
ventricular dysfunction, e.g. hypertension, angina pectoris and history of MI were added 
to model B (model C). All analyses were also done with fractional shortening as a 
continuous variable. Subgroup analyses were performed to examine whether age (above 
and below the median age (70» or gender modified the relationship between systolic 
dysfunction and (cardiovascular) mortality. 
Table 3: Left ventricular systolic (dys)function and risk for all cause mortality, cardiac death and sudden 
death. Hazard ratios with 95% confidence intervals are given for left ventricular dysfunction defined as a 
fractional shortening <25% and for fractional shortening as a continuous variable. 
Fractional All cause mortality Cardiac death Sudden death 
Shortening 
<25% 
Crude 3.3 (1.6·6.9) 6.3 (2.2-18.6) 8.1 (1.7-38.5) 
Model A 2.5 (1.2-5.2) 4.7 (1.6-13.9) 5.6 (1.2-27.2) 
ModelB 2.9 (1.4-6.0) 5.4 (1.8-16.5) 4.7 (0.9-23.8) 
Modele 2.4 (1.1-5.2) 3.9 (1.2-12.9) 3.3 (0.6-19.3) 
Continuous 
(per%) 
Crude 0.95 (0.93-0.98) 0.93 (0.89-0.98) 0.93 (0.86-1.00) 
Model A 0.96 (0.94-0.99) 0.94 (0.90-0.99) 0.95 (0.88-1.02) 
ModelB 0.96 (0.94-0.99) 0.94 (0.90-0.98) 0.95 (0.88-1.02) 
Modele 0.96 (0.94-0.99) 0.96 (0.91-1.00) 0.98 (0.91-1.06) 
Model A: adjusted for age and sex; Model B: adjusted for age, sex, body mass index, diabetes mellitus, 
use of COPD medication, smoking and cholesterol level; Model C: adjusted for age, sex, body mass 
index, diabetes mellitus, use of COPD medication, smoking, cholesterol level and hypertension, angina 
pectoris, history of myocardial infarction. COPD == chronic obstructive pulmonary disease. 
Results 
Table I shows the characteristics of the participants in the Rotterdam Study who 
underwent echocardiography. The participants with a technically inadequate 
echocardiographic recording were more likely to be older, had a higher body mass index 
and more often were hypertensive, smokers or used medication for chronic obstructive 
pulmonary disease (ATC-code R03). Of the 2270 participants with an adequate 
echocardiogram 73 (3.2% (95%CI 2.5-3.9» had impaired systolic function, i.e. a 
fractional shortening less than 25%. Compared to those with normal fractional 
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shortening, those with reduced fractional shortening were older and a larger proportion 
was male. In addition, they had a higher prevalence of a positive history of MI and 
angina pectoris and more often used COPD medication (Table 2). 
During the mean follow-up period of 3 years (maximum 6 years), 85 (4.3%) 
participants died; 24 (1.2%) died from a cardiac cause and 10 (0.5%) died suddenly. 
Figure I shows the Kaplan-Meier survival rates for all cause mortality for 
subjects with normal and impaired left ventricular systolic function. The mortality rate 
in the group with impaired left ventricular systolic function was significantly higher 
(p~0.0007). 
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Figure 1: Kaplan-Meier survival curves for all calise mortality in participants with nonnal and impaired 
systolic function. FS = fractional shortening. 
Participants with an impaired ventricular systolic function had an increased 
cmde relative risk for all cause mortality (hazard ratio (HR) 3.3; 95%CI 1.6-6.9), 
cardiac death (HR 6.3; 95%CI 2.2-18.6) and sudden death (HR 8.1; 95%CI 1.7-38.5), 
compared to those with a normal systolic function (table 3). For the population as a 
whole, for each percentage increase in fractional shortening the cmde relative risk was 
reduced by 5% (HR 0.95; 95%CI 0.93-0.98) for all cause mortality, 7% (HR 0.93; 
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95%CI 0.89-0.98) for cardiac death and 7% (HR 0.93; 95%CI 0.86-1.00) for sudden 
death. 
Adjustment for (other) cardiovascular risk factors lowered the hazard ratio 
estimates but, except for sudden death, the hazard ratios remained statistically 
significant. Subgroup analyses did not indicate that the risk was modified by gender and 
age (data not shown). 
Discussion 
Our study shows that left ventricular function, measured as the fractional shortening, is 
a strong predictor of all cause mortality, cardiac death and sudden death in the elderly 
popUlation at large. This increased risk is only partly attributable to other cardiovascular 
risk indicators. 
The overall response and completeness of follow-up of our study was high. 
Nevertheless, nOll-response and loss to follow-up may have led to an underestimation of 
the risks. Notably a lower response rate in diseased people with poorer prognoses could 
be of influence. 
2823 pa.1icipants of the Rotterdam study underwent echocardiography, e.g. 35% 
of the total population. This was largely due to the absence of echocardiographic 
facilities during certain periods, and is unlikely to have influenced our risk estimates. In 
addition, certain participants who did not undergo echocardiography when the device 
was available were not able to come to the research centre due to physical inability and 
comorbidity. This most likely led to underestimations of the risks. 
Due to the size of our study population, left ventricular dysfunction was 
estimated by fractional shortening, rather than by determining the ejection fraction. In 
the absence of wall motion abnormalities fractional shortening can be assumed to 
reliably reflect left ventricular systolic function. 13 The cardiovascular risk profile of 
participants in whom the echocardiographic recordings were deemed inadequate was 
less beneficial than in those with available echocardiographic interpretations. The risks 
for all cause mortality, cardiac death and sudden death in this group was lower than the 
risks of the participants with an impaired left ventricular dysfunction, but higher than in 
participants with normal systolic function (data not shown). Thus, inability to measure 
the left ventricular function also seems of prognostic importance. 
One could argue whether adjustment for cardiovascular risk indicators that are 
causally related to systolic dysfunction (such as hypertension and prior MI) is adequate. 
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However, although the risk estimales alternated after adjuslment, the value of left 
ventricular systolic dysfunction in predicting cardiac mortality persisted. 
Previous sludies established the prognostic importance of an impaired systolic 
function in patients wHh severe heart failure. survivors of a myocardial infarction or 
patients with other cardiovascular risk factors. 16•18 These studies were all based on 
selected patient populations of, usually symptomatic, treated patients. To our knowledge 
this is the first study to assess the prognostic importance of left ventricular dysfunction 
the elderly population at large. 
We conclude that left ventricular dysfunction is a strong and independent 
predictor of mortality in the elderly. Prevention and early detection and treatment of 
systolic dysfunction might lead to a significant reduction of mortality in the elderly. 
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Background 
Heart failure is a multifactorial clinical syndrome for which no universally accepted definition exists.' Heart failure is attributable to systolic andlor diastolic cardiac 
dysfunction (i.e. inability to contract normally and expel sufficient blood (systolic 
failure) andlor inability to relax and fill normally (diastolic failure)). Although heart 
failure is a disabling and invalidating condition, which carries a very poor prognosis and 
requires frequent hospital (re)admissions, data on its epidemiology are relatively 
scarce.' In this thesis various epidemiologic aspects of heart failure in the population at 
large, such as diagnosis, risk factors, incidence and prognosis were discussed. Most 
chapters are based on studies performed as part of the Rotterdam Study, a prospective 
follow-up study among all inhabitants of 55 years and older, living in the suburb 
Ommoord of Rotterdam.2 This final chapter will address the epidemiology of heart 
failure in view of our major findings, discllss the consequences of our findings for 
medical practice and will give suggestions for future research. 
Occurrence 
Estimates of the prevalence of asymptomatic and symptomatic left systolic ventricular 
dysfunction (i.e. heart failure) based on population-based studies using 
echocardiography were recently reported.3.1 Although discrepancies between the studies 
exist, all studies indicate that the prevalence of left ventricular systolic dysfunction 
(LVSD) and heart failure is high and increases with age. Furthermore, the majority of 
persons with LVSD is asymptomatic.4•5 No data on the occurrence of left ventricular 
diastolic dysfunction (LVDD) in the population at large are available. 
To reliably assess the incidence of heart failure, each person with signs and 
symptoms suggestive of heart failure should undergo a complete comprehensive 
cardiovascular work-up. Tltis approach was used in the Hillingdon Heart Failure Study 
and in chapter 4 by our own group.8 
Our study yielded higher incidence estimates than those reported in the 
Hillingdon Heart Failure Study, but probably provides the most representative incidence 
estimates in the population at large. The Hillingdon Heart Failure Study identified all 
their cases from hospital admissions and from referrals to an outpatient heart failure 
cliItic whereas we also identified the ones who where not admitted to the hospital or to 
the clinic. FurthemlOre, we tried to maximise sensitivity of case finding by training the 
GPs in the use of diagnostic screening tools. However, it should be emphasized that the 
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true incidence may even be somewhat higher in the population at large due to a higher 
non-response rates in unhealthy participants in the Rotterdam Study and also because 
we used a rather strict case definition.9•10 
Our age and gender specific incidence estimates of heart failure can be useful in 
estimating the magnitude of the health impact of heart failure in the elderly and could 
aid in future planning. Furthennore, our estimates show that, the "typical" heart failure 
patient (men and women, older than 70 years, usually with comorbidity and not all referred 
to secondary health care) has largely been excluded from clinical trials. I I 
Diagnosis 
The diagnosis of heart failure is difficult and represents a challenge to physicians, 
notably it's early stages. Correctly diagnosing heart failure is the basis of optimal 
clinical care for heart failure patients as it facilitates approaches to adequately treat and 
improve prognosis in these patients. 
As there is no gold standard for the diagnosis of heart failure, there is 
considerable variation in the methods to its diagnosis. Often the diagnosis of heart 
failure is primarily based on signs and symptoms. The validity of the clinical diagnosis 
of patients with heart failure is poor, however, especially in a primary care. 12- 14 The use 
of additional tests, preferably rapid, non~expensive and non-invasive, should be 
explored. For example, the additional diagnostic value of a test-treatment with 
furosemide, although recommended in two Dutch guidelines on management of heart 
failure. remains uncertain,15,16 Since such a test treatment is often applied in medical 
practice, studies exploring its value are warranted. 
Neurohonnones have recently been put forward as a potential diagnostic tool. It 
is known that, in order to maintain circulatory homeostasis, complex neuroendocrine 
and haemodynamic mechanisms are activated to compensate the loss of cardiac 
function, I? The neuroendocrine responses include activation of the sympathetic nervous 
system, activation of the renin-angiotensin-aldosterone (RAAS) system and release of 
natriuretic and vasoactive peptides. The activation of the sympathetic nervous system 
(norepinephrine) was first discovered in 1962 and since 1984 it has been known that the 
prognosis in patients with heart failure is inversely related to norepinephrine levels.l8 
The RAAS system is also activated and related to the prognosis in most patients with 
severe heart failure.l 9 Because plasma concentrations of natriuretic peptides are 
increased in early stages of heart failure, circulating levels of natriuretic peptides may 
be sensitive diagnostic markers of heart failure.2o-23 The detennination of 
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neurohormones used to be time consuming and expensive. Currently, rapid and 
relatively inexpensive (€ 23) assays for humoral measurements have become available, 
but these are still not widely used. Furthermore, it should be emphasized that 
measurement of neurohonnones merely indicates the presence or absence of heart 
failure and provides no objective measurement of the cardiac function nor indicates the 
presence of treatable underlying causes of heart failure.We observed that 
neurohormones are of considerable diagnostic value when added to the findings of 
history and physical examination (chapter 6). Therefore, the results of our study 
suggests that (until echocardiography is easily and inllnediately available and 
affordable) measurement of natriuretic peptides provides a useful alternative in routine 
clinical (general) practice in patients suspected of heart failure. It may also be useful in 
deciding whether or not to opt for echocardiographic investigation. 
In recent years Doppler echocardiographic has emerged as an important non-
invasive tool to diagnose heart failure, also in a non-hospital setting.22.25 According to 
the diagnostic of the Task Force on Heart Failure of the European Society of Cardiology 
objective evidence of cardiac dysfimction has to be present in addition to clinical 
symptoms to establish a diagnosis oflteart failure.26 Echocardiography is reconmlended 
as the key diagnostic tool to assess the presence of cardiac impairment. Therefore, 
ideally every patient suspected of heart failure should be screened by echocardiography 
to confirm the diagnosis. However, Doppler echocardiographic is not readily available 
for primary care physicians. Currently, in the Netherlands patients suspected of heart 
failure by the GP have to be referred to a cardiologist for echocardiographic 
investigation. This leads to a considerable time delay because of limited availability of 
rapid cardiologic consultation and also because of limited availability of 
echocardiographic resources. Furthermore, the patients referred frequently remain in 
secondary care for quite some time, often, unnecessarily, leading to higher costs. 
If echocardiograpy is to be used in all heart failure patients a more rapid, easily 
available and inexpensive echocardiographic service is needed such as the open access 
echocardiography operating in some places in the UK.24,25 There is, however, much 
debate on how tltis service should be delivered, as indicated by the number of comments 
and articles on the echocardiography in recent years.24,25,27-39 
It is now been recognized that a proportion of the patients with heart failure have 
normal systolic function, especially the elderly. In these patients ventricular diastolic 
fimction is decreased. Diastolic dysfunction prevents the ventricles from being filled 
adequately at normal atrial pressure.40 Until recently, no standardized method existed to 
diagnose left ventricular diastolic dysfunction. The European Study Group on Diastolic 
Heart Failure of the European Society of Cardiology has now proposed guidelines for 
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the diagnosis of diastolic heart failure in 1998.41 Still criteria used in the guideline were 
based on highly selected patient groups. Application of these criteria in the general 
population needs further study. A better understanding of the nature and implications of 
diastolic dysfunction is to be expected in the near future. 
Etiology 
Risk factors for the development of heart failure in the popUlation at large have been 
examined in the late eighties using relatively non-sensitive methods to establish the 
diagnosis of heart failure.42-44 We used more objective measurements of cardiac 
function, enhancing the accuracy of the heart failure diagnosis and confirmed the role of 
several established risk factors for heart failure such as history of myocardial infarction, 
diabetes, hypertension, peripheral arterial disease and obesity. In addition, an 
electrocardiographic T axis abnormality was a strong risk factor of heart failure. Since 
abnormal T axis is a marker of ischaemic myocardial damage (Le. abnormalities due to 
ischaemic changes), this again indicates that coronary artery disease clearly increases 
the risk of heart failure. By calculation of etiologic fractions (proportion of exposed 
cases * (RR-I)/RR. 100) one can estimate the proportion of disease that is attributable 
to risk factors. The proportion of heart failure that may be attributed to the strongest risk 
factors (history of myocardial infarction, diabetes, hypertension, peripheral arterial 
disease and electrocardiographic T axis abnormalities) is estimated to be as high as 
70%. 
Prognosis 
Information on the prognosis of asymptomatic left ventricular systolic and diastolic 
dysfunction and of heart failure in unselected patients is limited. 
To our knowledge our studies are amongst the first to show that the prognosis of persons 
with heart failure or with left ventricular systolic dysfunction in the population at large is 
poor. Several studies have demonstrated the prognostic benefits of treatment of 
symptomatic left ventricular dysfunction (Le. heart failure).45.5o Asymptomatic systolic 
left ventricular dysfunction is increasingly being recognized as an important precursor 
of heart failure; 30% of the participants in the Studies of Left Ventricular Dysfunction 
(SOLVD) Prevention Trial with asymptomatic impaired systolic function developed 
symptoms within three years.47 Theoretically, prevention and early detection and 
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treatment of asymptomatic systolic dysfunction might lead to a significant reduction in 
mortality. 
Management 
The development of heart failure can be delayed or prevented by a number of 
interventions that reduce the risk of developing left ventricular dysfunction and decrease 
it's progression. Interventions should be directed at modifiable risk factors of heart 
failure (Le. coronary heart disease, hypertension, diabetes) and at limiting myocardial 
injury (Le. thrombolytic therapy, PTCA, CABG). However, paradoxically, the success 
of treatment of acute coronary artery disease, valvular diseases and hypertension, 
creates a growing group of older people who are at risk of developing heart failure and a 
clear increase in the prevalence ofhcart failure,51 
Treatment strategies in heart failure have changed markedly in recent decades, 
and the currently available treatment options have unequivocally been shown to reduce 
morbidity and mortality.45,47,s2 This, however, further contributes to the increasing 
prevalence of heart failure. Currently, improved diagnostic tools such Doppler 
echocardiography, ultrafast magnetic resonance imaging (MRI), electron-beam 
computed tomography (EBCT) scanning and neurohormones are available to diagnose 
heart failure and its precursor left ventricular dysfunction and the view that there are 
oppOltunities for preventive therapeutic interventions have fuelled discussions regarding 
the possibility of screening for heart failure and/or asymptomatic LVSD. 
However, to justify screening for heart failure or asymptomatic left ventricular 
systolic function to be worthwhile, several criteria must be fulfilled as suggested by 
Wilson (table 1).53 Currently, the most important criteria, such as knowledge on natural 
history, efficacy and the cost-effectiveness are still unknown. The natural history of 
asymptomatic left ventricular dysfunction is still not fully understood. Consequently, a 
detailed strategy (frequency of screening, at which age the screening be should initiated 
and who should be screened, e.g., all people or high risk subjects, how the 
echocardiographic service is to be organised and the number of echocardiographic 
facilities needed) cannot be developed. The efficacy of the drug treatment (Le. ACE-
inhibition) in asymptomatic LVSD has not been studied in the most relevant patient 
groups (men and women above the age of 70 years men and women, usually with 
comorbidity). Furthermore, the cost-effectiveness of detecting and treating 
asymptomatic L VSD is unknown. Therefore, research aimed at comparing the effect of 
screening and early treatment of asymptomatic L VSD to a strategy involving initiating 
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treatment when symptoms develop is needed. For screening for heart failure almost the 
same is true; there is no screening strategy and the cost-effectiveness of screening has 
not been evaluated. 
In theory the prognosis of heart failure can be improved by early delection of 
and optimal treatment of heart failure. In the Netherlands, and in some other countries, 
most heart failure patients are diagnosed and treated by GPs.13 As mentioned above, 
optimisation of detection of heart failure by GPs can be established by providing 
adequate resources for diagnosis, such as open-access echocardiography or 
neurohumoral measurements. Although there are several guidelines reconnnending the 
use of ACE inhibitors, these dntgs are still under-utilized and prescribed in sub-optimal 
dosage, in both primary care and secondary care.54-58 Implementation of 
recommendations in clinical practice is important. Furthennore, since heart failure is a 
disease oflhe elderly, clinical trials should also include the elderly heart failure patients, 
especially those managed in primary care. As heart failure progresses, hospital 
admission and readmission is almost inevitable. Presently, the number of hospital 
(re)admissions is high and rising, hospital admissions are expensive and that there is a 
decreased availability of hospital beds.59 Non-compliance with management (such as 
with drug treatment and diet) is anlOng the most important problems in patients with 
heart failure.60 Several small studies evaluating the effect of non-pharmacological 
management programs, have been published recently and they suggest that a nurse-
directed, multidisciplinary treatment strategy can improve quality of life and reduce 
hospital readmissions in patients with heart failure.61 -64 The benefit in terms of 
readmissions and quality of life of these studies should be evaluated further in larger 
studies. 
Conclusions 
Heart failure is a major health problem and its magnitude is expected to increase 
considerably in the near future. Current knowledge of heart failure and of asymptomatic 
left ventricular systolic function is increasing but much progress can be made in the 
diagnosis and management of the disease. 
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Summary 
Heart failure is one of the conmlonest cardiovascular disorders in Western Society, especially in the elderly, and is still a growing major public health problem due to 
the expected increase in the number of elderly. Despite the fact that heart failure and its 
precursor left ventricular systolic dysfunction are increasingly being recognised as 
important causes for morbidity and mortality, epidemiologic data are scarce. [n this 
thesis, various epidemiologic aspects of heart failure and its precursor left ventricular 
systolic function are described. 
Chapter 2 presents an overview on the current epidemiological knowledge 
about asymptomatic left ventricular systolic function in the population at large, based on 
literature data. An important reason for the lack of epidemiologic data is that 
echocardiography, currently recommended as the diagnostic tool to assess the left 
ventricular systolic function (LVSD), has only recently been used in population-based 
studies. LVSD is common, more frequent with age and is higher in men than in women. 
About half of the LVSD patients are asymptomatic. Data on incidence, etiology, 
prognosis and management ofLVSD is scarce and urgently needed. 
The diagnosis of heart failure is difficult, especially in primary care. A heart 
failure score might be a useful screening test to identifY possible heart failure cases. In 
chapter 3 the interohserver variation among general practitioners in the use of a scoring 
system to detect possible heart failure is studied. Five GPs and one cardiologist were 
asked to examine 15 patients and fill in a heart failure score. [ntraclass correlation 
coefficients were calculated to determine the reproducibility of the score. The 
interobserver agreement on the presence of heart failure and on signs and symptoms of 
heart failure was low and agreement on referral was good and correct. We concluded 
that when the aim is referral of Ihose with possible heart failure a heart failure score 
appears to be a useful tool. 
In chapter 4 the incidence and management of heart failure in general practice 
in the Netherlands is described. We used data from the Dutch National Survey of 
Morbidity and Interventions in General Practice (NlVEL) carried out in 1987 and 1988 
and data of the Rotterdam General Practitioners Project (ROHAPRO)-database from 
1991-1997. In 1987-88 the overall incidence rate of heart failure in those aged 55 years 
or over was 11.3 per 1000 person years (95% CI9.8-l2.9). The incidence rate increased 
from 2.7 per 1000 person years in men aged 55-64 to 27.8 per 1000 person years in men 
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aged >75 years and for women in the same age-categories from 1.7 per 1000 person 
years to 33.3 per 1000 person years, respectively. Of the 210 incident cases of heart 
failure, 45 (21%) were referred to a specialist. In 1987-1988 dmgswere prescribed by 
the GP in 162 of the incident cases (77%); 90 patients received a loop diuretic, 48 
another diuretic while only seven patients received an ACE-inhibitor. In 86% of patients 
diagnosed with heart failure from 1991 till 1997, medication was prescribed; notably a 
diuretic (93%), ACE-inhibitors (51%) and digoxin (40%). About half was referred to a 
cardiologist. We conclude that the incidence rate of heart failure in general practice is 
high in both men and women and clearly increases with age. In contrast to most current 
clinical guidelines only a minority of the heart failure patients was referred to a 
specialist and many patients with heart failure do not receive ACE-inhibition. 
In cbaptcl' 5 the incidence of heart failure and the risk factors for heart failure in 
an elderly general population sample were studied. During 23 months of follow-up, all 
new cases of heart failure were identified among 5281 participants of the Rotterdam 
Study. Three methods to detect possible cases were used; diagnostic work-up at a rapid-
access clinic of possible heart failure cases referred by GPs, computerised GP registries, 
and phannacy data. The diagnostic work-up included echocardiography, exercise testing 
and neurohumoral measurements, Of all possible cases additional data were collected 
from the patients' medical records. A panel of a cardiologist, internist, general 
practitioner and clinical epidemiologist reviewed all collected data to classify the cases. 
Cox' proportional hazards regression analysis was used to identifY potential risk factors 
for heart failure. The overall incidence was 13.2 per 1000 patient years (95% CI 11.6-
20). The incidence rate increased from 2.1 per 1000 person-years in those aged 55-64 to 
43.4 in those aged 85 years and over. Increased age, male gender, higher body mass 
index, history of myocardial infarction, diabetes, hypertension, peripheral arterial 
disease, electrocardiographic Taxis abnom13lities and higher fibrinogen levels appeared 
to be independent risk factors for heart failure. Thus the incidence of heart failure in the 
elderly is high and exponentially increases with age. blsight in risk factors enables 
targeted preventive strategies. 
As mentioned above the diagnosis of heart failure is difficult, particularly in 
general practice where the diagnosis is primarily based on signs and symptoms. 
Additional diagnostic tests (including measurement of neurohormones) might improve 
the accuracy of the diagnosis of heart failure in the absence of echocardiography. In 
cbapter 6 we evaluated and compared the performance of different diagnostic strategies 
in primary care patients suspected of heart failure. 149 patients in whom the GP 
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suspected heart failure were referred to a research centre for a diagnostic work-up. The 
work-up consisted of history taking, physical examination, ECG, chest X-ray, 
echocardiography and measurement of neurohormones. An expert panel reviewed all 
data and decided on the presence or absence of heart failure. Multivariate logistic 
regression analyses were used to construct diagnostic models. To compare the 
diagnostic performance of the different diagnostic strategies we used ROC areas and 
subsequently the positive and negative predictive values of the models were compared. 
The diagnostic model including history variables only yielded a ROC area of 0.75. The 
consecutive addition of physical examination, chest X-ray and ECG increased the ROC 
area to 0.78, 0.84 and 0.90, respectively. The model with history, physical examination 
and ECG had a ROC area of 0.89. Addition of the chest X-ray findings yielded a higher 
ROC area but the predictive values did not improve. Neurohormones further increased 
the ROC areas. Compared to the history, physical examination and ECG model the 
models containing one of the studied neurohonnones and history and physical 
examination alone produced similar ROC areas. In addition, the history, physical 
examination and ANP model classified the patients better than the history, physical 
examination and ECG model. The data suggest that neurohormone levels can improve 
diagnostic accuracy in patients suspected of heart failure. 
Chapter 7 describes a study on the prognosis of heart failure in the general 
population. In 5255 Rotterdam Study participants (age 68.9 ± 8.6 years, 3113 women) 
the presence of heart failure was determined and baseline variables were obtained at the 
first examination taking place from 1990 to 1993. Information on vital status, fatal and 
non-fatal endpoints was obtained from the municipal health authorities, general 
practitioners and hospital records. 181 participants (age 77.3 ± 7.9 years, 109 women) 
had heart failure. Of these 85 (47%) persons died during the 4.8 - 8.5 (mean 6.1) years 
of follow-up. One, two and five years' survival was 89%, 79%, and 59%, representing 
an age-adjusted mortality twice (hazard ratio 2.1, 95% CI 1.8-2.7) that of persons 
without heart failure. The hazard ratio for sudden death was even more pronounced: 4.8, 
(95% CI 2.6-8.7). Heart failure generally afflicts older persons in the community and 
carries a poor prognosis. Having heart failure confers a fivefold increase in the risk of 
sudden death. 
In chapter 8 we investigated the prognostic value of left ventricular systolic 
dysfunction in the population at large. 2823 echocardiograms were available in the 
population-based Rotterdam Study, among men and women aged 55 years and older. 
Fractional shortening (FS) was determined in 2270 and used as an index for systolic 
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function. Follow-up data was available for 86%. The association between systolic 
dysfunction (FS <25%) and all cause mortality, cardiac death and sudden death was 
examined using Cox' proportional hazards model. During a mean follow-up period of 3 
years (maximum 6 years), 85 (4.3%) participants died; 24 (1.2%) died from a cardiac 
cause and 10 (0.5%) died suddenly. Subjects with an impaired ventricular systolic 
function had a cnIde increased relative risk (hazard ratios) of3.3 (95%CI 1.6-6.9) for all 
cause mortality, 6.3 (95%CI 2.2-18.6) for cardiac death and 8.1 (95%CI 1.7-38.5) for 
sudden death. Adjustment for (other) cardiovascular risk factors reduced the risk 
estimates but these remained statistically significant, except for sudden death. Analyses 
using fractional shortening as a continuous variable showed that with each percentage 
increase in fraclional shortening risks of cardiac death reduced by approximately 7% 
(95%CI 2-11). Left ventricular systolic dysfunction is a strong independent predictor of 
mortality in the general population. 
Finally, in chapter 9, the general discussion the implications of the studies 
described in this thesis are discussed and recommendations for future research are 
given. 
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Samenvatting 
H artfalen is, met name bij Quderen, cen van de meest voorkomende hart-en vaatziekten in de westerse landen en zal, met name door de veroudering van de 
bevolking een steeds belangrijker volksgezondheidsprobleem worden. Ondanks het feit 
dat hartfalen en systolische linker ventrikel disfunctie (de voorloper van hartfalen) 
steeds vaker erkend worden als belangrijke oorzaken van morbiditeit (ziekte) en 
mortaliteit (sterfte), zijn epidemiologische gegevens schaars. In dit proefschrift worden 
verschillende epidemiologische aspecten van hartfalen en systolische linker ventrikel 
disfunctie heschreven. 
In hoofdsluk 2 wordt een overzicht gegeven van de huidige epidemiologische 
kelmis op het gebied van asymptomatische systolische linker ventrikel disfunctie in de 
aigemene populatie, aan de hand van cen Iiteratuuroverzicht. Tot voorkort waren weinig 
epidemiologische gegevens beschikbaar. Een belangrijke oorzaak voor het ontbreken 
van epidemiologische gegevens is het feit dat de echocardiografie, die momenteel 
beschouwd wordt als de standaard om systolische linker ventrikel disfunctie te 
diagnosticeren, pas recent toegepast wordt bij bevolkingsonderzoek. Vit deze 
onderzoekingen blijkt dat systolische linker ventrikel disfunctie frequent voorkomt, dat 
de prevalentie stijgt met het toenemen van de leeftijd en hoger is bij mannen dan bij 
vrouwen. Ongeveer de helft van de patienten met systolische linker ventrikel disfunctie 
heeft geen k1achten passend bij hartfalen. Additionele epidemiologische gegevens over 
de incidentie, de etiologie, de prognose en het beleid bij systolische linker ventrikel 
disfunctie zijn nodig. 
Het stcllcn van de diagnose hartfalen is niet eenvoudig, met name in de eerste 
lijn. Een hartfalen scorelijst zou een nuttig hulpmiddel kunnen zijn om mogelijk 
hartfalen op te sporen. In hoofdstuk 3 wordt een onderzoek naar de onderlinge 
Qvereenstemming van huisartsen bij het gebruik van cen hartfalen scorelijst beschreven. 
Vijf huisartsen en een cardioloog werd gevraagd 15 patienten te onderzoeken en een 
hartfalen scorelijst in te VlIUen. Intra class correlatie coefficienten werden berekend om 
de reproduceerbaarheid van de score te bepaJcn. Hieruit bleek dat de "tussen persoon" 
Qvereenstemming over de aanwezigheid van hartfalen en de bevindingen bij anamnese 
en lichamelijk onderzoek laag was. De "tussen persoon" overeenstemming over het weI 
of niet verwijzen van een van hartfalen verdachte patient daarentegen was goed. Een 
scorelijst met als doel de selectie voor het verwijzen van mogelijke hartfalen patienten 
te ondersteunen lijkt dus een nuttig hulpmiddel te zijn. 
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In hoofdstuk 4 wordt de incidentie en het beleid van hartfalen in de 
huisartsenpraktijk beschreven. Wij maakten daarbij gebruik van gegevens van de 
Nationale Studie naar ziekten en verrichtingen in de huisartsenpraktijk (NIVEL) 
uitgevoerd tussen 1987 en 1988 en van gegevens van het Rotterdams Huisartsen Project 
(ROHAPRO) verzameld tussen 1991 en 1997. In 1987-88 was de incidentie van 
hartfalen bij personen van 55 jaar en ouder 11,3 per 1000 persoonsjaren (Pj) (95% 
betrouwbaarheidsinterval (BI) 9,8-12,9). De incidentie nam toe van 2,7 per 1000 pj bij 
mannen in de leeftijd van 55-64 jaar tot 27,8 per 1000 pj bij mannen van 75 jaar en 
ouder en bij vrouwen in dezelfde leeftijdscategorieen van 1,7 per 1000 pj tot 
respectievelijk 33,3 per 1000 pj. Van de 210 incidente gevallen van hartfalen werden er 
45 (21%) verwezen naar een specialist. In 1987-1988 werd bij 162 (77%) patienten een 
medicijn voorgeschreven: 90 kregen een Iis-diureticum, 48 een ander diureticum en 
maar 7 patienten kregen een ACE-remmer. In de periode tussen 1991 en 1997 werd bij 
86% van de hartfalen patienten medicatie voorgeschreven, dit betrof diuretica (93%), 
ACE-rennners (51%) en digoxine (40%). Ongeveer de helft van de hartfalen patienten 
was ooit verwezen naar cell cardioloog. Deze resultaten Iaten zlen dat de incidentie van 
hartfalen in de huisartsenpraktijk hoog is bij zowel mannen als vrouwen en stijgt met 
het toenemen van de leeftijd. In tegenstelling tot de meeste beschikbare richtlijnen over 
hartfalen, wordt ceo minderheid van de hartfalen patienten verwezen wordt naar cen 
specialist en wordt bij veel hartfalen patienten geen ACE-remmer voorgescbreven. 
In hoofdstuk 5 wordt een onderzoek naar de incidentie en de risicofactoren van 
hartfalen in de algemene bevolking beschreven. Gedurende een follow-up peri ode van 
23 maanden werden 5281 deelnemers van het Erasmus Rotterdam, Gezondheid en 
Ouderen (ERGO) onderzoek gevolgd om aIle nieuwe gevalIen van hartfalen op te 
speren. Er werden 3 methoden gebmikt om mogelijke nienwe gevalIen van hartfalen op 
te sporen: een snel toegankelijke diagnostische hartfalen polikliniek waarnaar huisartsen 
potentiele hartfalen patienten konden verwijzen, gegevens nit een geautomatiseerd 
huisartsen informatiesysteem en infonnatie uit cen geautomatiseerd apothekersbestand. 
Het diagnostisch onderzoek op de diagnostische polikliniek bestond onder andere uit 
echocardiografie, inspanningstesten en het meten van de neurohumorale parameters in 
het bloed. Verder werd van aUe mogelijke incidente patienten additionele informatie uit 
de medische status bij de huisarts verkregen. Aan de hand van aIle verzamelde gegevens 
bepaalde een panel (bestaande uit een cardioloog, een internist, een huisarts en een 
klinisch epidemioloog) of er weI of niet sprake was van incident hartfalen. Cox' 
proportional hazard regressie analyses werden gebrnikt om risicofactoren voor hartfalen 
op te sporen. De incidentie van hartfalen was 13,2 per 1000 pj (95% BI 11,6-20,0). De 
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incidentie nam toe van 2, I per 1000 pj bij patienten in de leeftijd van 55-64 jaren tot 
43,4 per 1000 pj bij patienten van 85 jaar en ouder. Dit laat zien dat de incidentie van 
hartfalen bij ouderen hoog is en exponentieel stijgt met het toenemen van de leeftijd. 
Onafhankelijk risieofaetoren voor het optreden voor hartfalen waren oudere leeftijd, 
mannelijk geslacht, obesitas, een myoeard infarct in de voorgeschiedenis, diabetes 
mellitus, hypertensie, perifeer arlerieel vaatlijden, abnormale T-as op het 
electrocardiogram en hogere semm fibrinogeen concentraties. Verder inzicht in de rol 
van risieofactoren bij het ontstaan van hartfalen kan gebmikt worden bij de 
ontwikkeling van maatregelen ter voorkoming van hartfalen. 
Zoals hierboven reeds vermeld, is hartfalen moeilijk te diagnosticeren, met name 
in de huisartsenpraktijk. De huisarts stelt zijn diagnose hartfalen met name op grond van 
de bevindingen bij anamnese en liehamelijk onderzoek. Aanvullend onderzoek (onder 
andere het meten van de neurohormoon concentraties in het hloed) zou illdien 
echoeardiografie niet besehikbaar is de betrouwbaarheid van de diagnose hartfalen 
kmmen verbeteren. In hoofdsluk 6 wordt de nauwkeurigheid van verschillende 
diagnostisehe strategieen zoals die toegepast zouden kmmen worden in de 
huisartsenpraktijk bij patienten verdaeht van hartfalen vergeleken. Door huisartsen 
werden 149 patienten met de verdenking hartfalen doorgestuurd naar onze 
hartfalenpolikliniek voor verdere diagnostiek. De diagnostiek bestond uit anamnese, 
lichamelijk onderzoek, elektrocardiogram, thoraxfoto, echocardiogram en het meten van 
de neurohonnonen. Een expert panel bekeek alle informatie en besliste of hartfalen wei 
of niet aanwezig was. Multivariabele regressie analyses werden gebmikt om 
diagnostische modellen te maken. Voor het vergelijken van de nauwkeurigheid van de 
versehillende diagnostische modellen gebruikten we Receiver Operating Characteristics 
(ROC) curven en de positieve en negatieve voorspellende waarde van de modellen 
vergeleken. Het model met alleen de anamnese variabelen had een oppervlakte onder de 
ROC curve van 0,75. Het achtereenvolgens toevoegen van lichamelijk onderzoek-, 
thoraxfoto- en ECG variabelen verhoogde de oppervlakten onder de ROC curven naar 
respectievelijk 0,78, 0,84 en 0,90. Het model met anamnese-, lichamelijk onderzoek- en 
ECG variabelen had een oppervlakte onder de ROC curve van 0,89. Het toevoegen van 
de thoraxfoto variabelen vergrootte de oppervlakte onder de ROC curve weliswaar 
enigszins, maar de positieve en negatieve voorspellende waarde van het diagnostische 
model verbeterde niet. Toevoeging van neurohonnonen vergrootte de oppervlakte onder 
de ROC curve verder. In vergelijking met een diagnostisch model met ananmese-, 
liehamelijk onderzoek- en ECG variabelen had een model met anamnese-, lichamelijk 
onderzoek variabelen en een van de neurohormonen een vergelijkbare oppervlakte 
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onder de ROC curve. Het model met anamnese, lichamelijk onderzoek en het 
neurohormoon ANP classificeerde de pati~nten beter dan het model met anamnese-, 
lichamelijk onderzoek- en ECG variabelen. Vit ooze gegevens kan worden afgeleid dat 
het bepalen van neurohormonen de accuratesse van de diagnostiek van patienten 
verdacht van hartfalen kan verbeteren. 
In hoord,luk 7 wordt de prognose van hartfalen in de algemene bevolking 
onderzocht. Bij 5255 deelnemers van het ERGO onderzoek (gemiddelde leeftijd 68,9 ± 
8,6 jaar, 3133 vrouwen) werden tijdens de eerste onderzoeksronde van ERGO (1990-
1993) verschillende variabelen gemeten en de aanwezigheid van hartfalen vastgesteld. 
Vit gegevens van de gemeente, de huisartsendossiers en brieven afkomstig van 
specialisten, werd informatie verkregen over het eventuele overlijden van de deelnemer 
en het optreden van hart- en vaatziekten. Bij het eerste ERGO bezoek hadden 181 
deelnemers (gemiddelde leeftijd 77,3 ± 7,9 jaar, 109 vrouwen) hartfalen. Hiervan 
overleden er 85 (47%) gedurende de follow-up periode. De 1-, 2- en 5 jaars overJeving 
waren respectievelijk 89%, 79% en 59%, overeenkomend met cen twee maal zo groat 
risico (gecorrigeerd voor leeftijd) op sterfte (hazard ratio HR 2,1: 95% BI 1,8-2,7) ten 
opzichte van deelnemers zonder hartfalen. Het risico te overlijden aan een plotselinge 
hartdood was nog hoger: ruim 4,8 (95% BI 2,6-8,7) keer zo hoog. Deze resultaten 
illustreren dat hartfalen optreedt op hogere leeftijd en een slechte prognose heeft. 
In hoofdsluk 8 wordt de prognostische waarde van systolische linker ventrikel 
disfunctie in de algemene bevolking beschreven. Cardiale echografie~n waren 
beschikbaar van 2823 ERGO-deelnemers van 55 jaar en ouder. Fractional shortening 
(FS) werd gebruikt als maat voor de systolische functie en deze kon worden bepaald bij 
2270 deelnemers. Complete follow-up gegevens waren beschikbaar van 86% van deze 
deelnemers. De relatie tussen systolische disfunctie (FS<25%) en sterfte (ongeacht de 
oorzaak), sterfte ten gevolge van cardiale oorzaken ell plotselinge dood werd bestudeerd 
met behulp vall Cox' proportional hazards modellen. Gedurende een gemiddelde 
follow-up periode van 3 jaar (maximaal 6 jaar) overleden 85 deelnemers (4.3%), 24 ten 
gevolge van cardiale aandoeningen en bij 10 was er sprake van een plotselinge 
hartdood. Deelnemers met een verminderde linker ventrikel fimctie hadden 
(ongecorrigeerd) een 3,3 (95% BI 1,6-6,9) maal verhoogd risico op sterfte, een 6,3 
(95%BI2,2-18,6) maal verhoogd risico op cardiale sterfte en een 8,1 (95%BI 1,7-35,5) 
maal verhoogd risico op plotselinge dood. COffectie voor (andere) cardiovasculaire 
risicofactoren verkleinde deze relatieve risico's maar deze bleven statistisch significant 
verhoogd, behalve het risico op plotselinge dood. Analyses met fractional shortening als 
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continue variabele Heten zien dat met iedere procent stijging van de fractional 
shortening het risico van sterfte afneemt met ongeveer 7 %. Hieruit blijkt dat de 
systolisehe linker ventrikel disfunetie een sterke en onafhankelijke risico-indieator is 
voor sterfte in de algemene bevolking. 
Tenslotte worden in hoofdsluk 9 worden de resultaten van de versehillende in 
het proefsehrift besehreven onderzoekingen bediseussieerd en worden aanbevelingen 
voor toekomstig onderzoek gegeven. 
Samenvallillg 

137 
Dankwoord 
D it proefschrift is tot stand gekomen door een samenwerking tussen de afdelingen Epidemiologie & Biostatistiek en de vakgroep Huisartsgeneesknnde. Dankzij een 
groat aantal menscn die op zeer uiteenlopende wijze cen bijdrage hebben geleverd, is dit 
boekje geworden wat het is. Ik ben dan ook veel mensen dank verschuldigd. Zonder 
iemand tckort te willen doell, wil ik cen aantal personen graag met name noemen en 
bedanken. 
Allereerst dank ik mijn beide promotoren, prof.dr A.W. Hoes en prof.dr D.E. 
Grobbee voor hun inzet bij het realiseren van dit proefschrift. De schrijfvaardigheid, 
inhoudelijke kennis, ervaring en ideeen op het gebied van hartfalen en klinische 
epidemiologie van Amo en Rick zijn overal in dit proefschrift terug te vinden. Amo was 
de geestelijke vader van dit onderzoek. Het idee om een huisarts (Jeanne) aan hel 
"hartfalen team" toe te voegen bleek een meesterlijke zet. 
Jeanne van der Schoot was van groot belang voor het slagen van dit onderzoek. 
Zij zorgde ervoor dat de huisartsen (haar jongens) alert bleven en deelnemers 
aanmeldden bij de hartfalen-polL Daarnaast heeft zij een belangrijk deel van de follow-
up verdcht. Collega's, assistentes en apothekers heeft zij om assistentie gevraagd op cen 
manier zaals aileen zij dat kan. Haar coli ega's waren zelfs op hun vakantie-adres niet 
veilig. Verder heeft ze haar eigen patienten gemobiliseerd om als sludieobject te dienen 
voor hoofdstuk 3. Pieter, haar man, werd bij gebrek aan financiele middelen direct 
ingezet als chauffeur. Mede door haar heb ik een bredere blik op de 
huisartsgeneeskunde gekregen. Jeanne, bedankt. 
Zander de medewerking van de huisartsen in Ommoord was cell groat deel van 
dil proefschrift niet mogelijk geweest. De gastvrijheid, de behulpzaamheid bij het 
opzoeken gegevens van patienten en het aanmelden en soms overhalen van deelnemers, 
maakte een aantal hoofdstukken van dit proefschrift mogelijk. 
Verder gaat mijn dank uit naar de vele deelnemers die bereid waren dee! te 
nemen aan het ERGO-onderzoek. Met name naar degencn van het hartfalenonderzoek 
die zich uitgebreid lieten onderzoeken. 
Dr. A.H.H.M. Balk, prof.dr. A.J. Man in 't Veld, prof.dr. A. Prins, dr. F.A.M. 
Jonkman en dr. A.H. van den Meiracker Illaakten deel uit van het panel en van de 
stuurgroep. Vele avonden gaven zij zinvolle suggesties en beoordeelden ze honderden 
patientencasussen. Ik wil hen danken voor hun enorme inzet. 
Voor het bepalen van de neurohormonen ben ik de mensen van het laboratorium 
Inwendige Geneeskunde I en met name Frans Boomsma} zeer erkentelijk. 
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Ook wil ik aile overige medewerk(st)ers en collega's die betrokken waren bij het 
ERGO-onderzoek, danken voor hun inzet bij het verzamelen van de gegevens. 
Dankbaar kon ik verder bouwen op de fundamenten die Arend Mosterd en Carl 
Moons hadden gelegd. Bedankt voor de aangename samenwerking. 
Elly Hagman, Eva Visscher en Agnes van der Voorn wil ik bedanken voor hun 
bijdrage aan de praktische afwerking van het onderzoek. Daaraan hebben oak Anneke 
(Chanel) Korving, Lydia Buist, Dick Slofen Taos Stehrnano hun bijdragen geleverd. 
Alfons Bongaerts dank ik voor het interpreteren van de thoraxfoto's. 
Graag wil ik ook aile medewerk(st)ers van de afdeling Epidemiologie en 
Biostatistiek en het huisartseninstituut bedanken. Een aantal wil ik er met name 
naemeo: Pieter van de Berg, Wouter Meijer, Paul van dec Linden, Hans Feenstra, 
Nicole van Popele, Caroline van Rossum, Iris Westendorp, Liesbeth Hak, Marc 
Bruijnzeels, Ben Ponsioen en RODs Bernsen. Met Pieter en WOllter heh ik vele uren 
doorgebracht op het huisartseninstituut, op cursussen, tijdens congressen en in eell 
kleine Nissan Micra met een hele grote koffer. Pieter, met wie ik jaren een kamer heb 
mogen delen, wil ik danken voor zijn luisterend oor, zijn hulp bij allerlei uiteenlopende 
problemen en zijn muzikaal onthaal. Het zal je vast goed afgaan als huisarts. Hierbij wil 
ik je oak een advies geven voor als je Doit een overvol spreekuur hcht: radio aan en 
gewoon meezingen en neurien. \Vollter, ik zal kart zijn, ik dank je voor je vricndschap 
en bijstand in goede en slechte tijden. 
Tevens wil ik oak Marcel en Frans bedanken voor hun steun, advies en 
vriendschap vanaf het moment dat we elkaar ontmoetten op het schaolplein tot aan de 
verdediging van dit baekje en ik hoop tot ver daarna. Hang loose, en laat de weergoden 
met DOS zijn. 
Henoy en Tineke (mijn schaonauders) wil ik bedanken voar al hun steun, 
belangstelling, advies en opvang van Thijs. 
Pa en Ma, jullie stelden mij in de gelegenheid am te studeren. Dank voar jullie 
goede zorgen, steun, belangstelling, en het feit dat jullie er altijd voor mijlons zijn. 
Sandra,je blijft altijd m'n kleine Z\lS. 
Tot slot, lieve Guyonoe en mijn kleine boef Thijs, het is moeilijk am ten 
overstaan van iedereen die dit leest eens even kart uit te leggen hoe belangrijk jullie 
voor mjj zijn. Jullie zijn voor mij in vele opzichten van onschatbare waarde. Guy, 
hartelijk dank voor je hulp, liefde, begrip, en geduld. 
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